Preparation method and intermediate of tricyclic compound

CN118974045APending Publication Date: 2024-11-15SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028722.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-15
Filing Date
2023-03-21
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing synthetic routes for FXI inhibitors are complex and the steps are cumbersome, resulting in low yields and cannot be effectively simplified.

Method used

The strategy of first synthesizing the imidazole ring and then the 2-pyridone heterocycle was adopted to simplify the synthesis process of compound 36 and its analogs, and improve the synthesis efficiency and yield by introducing new intermediates.

Benefits of technology

It simplifies the synthesis steps of the compound, increases the yield, reduces the generation of by-products, reduces the synthesis cost, and avoids racemization of the chiral center, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974045A_ABST
    Figure CN118974045A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a tricyclic compound and an intermediate thereof, and particularly discloses a method for preparing a compound shown in a formula (I-10) or an optical isomer thereof, the method is characterized in that a compound shown in a formula (I-8) is contacted with a compound shown in a formula (I-9), and the compound shown in the formula (I-10) or the optical isomer thereof is obtained. The yield is high. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Preparation method of tricyclic compounds and intermediates thereof

[0001] This application claims the priority of Chinese Patent Application No. 202210281242.7 filed on March 21, 2022, and the priority of Chinese Patent Application No. 202310251960.4 filed on March 15, 2023. This application incorporates the entirety of the aforementioned Chinese patent applications. Technical Field

[0002] The present invention belongs to the field of medicinal chemistry, and in particular relates to a preparation method of tricyclic compounds and intermediates thereof. Background Art

[0003] Coagulation factor XI (FXI) is a plasma serine protease essential for maintaining the intrinsic pathway. Upon activation, it generates activated coagulation factor XIa (FXIa), which plays a key role in the amplification of the coagulation cascade. During the coagulation cascade, thrombin can feedback activate FXI, which in turn stimulates the production of large amounts of thrombin, thereby amplifying the coagulation cascade. Therefore, drugs targeting FXI can block the intrinsic pathway and inhibit the amplification of the coagulation cascade, thereby exerting antithrombotic effects. Recent clinical data linking human factor XI (FXI) deficiency or elevated FXI levels with the development of thrombotic diseases, as well as experimental antithrombotic studies in animals with FXI deficiency, knockout, or inhibition, have demonstrated that FXI inhibition may reduce the risk of bleeding compared with direct FXa inhibitors, making it a novel target for antithrombotic prevention and treatment.

[0004] Currently, some patent applications for FXI inhibitors have been published, including: WO2016093285A1, WO2020259668A1, etc.

[0005] Patent application WO2020259668A1 (publication date: December 30, 2020) discloses a new FXI inhibitor, the general formula of which is At the same time, the patent application also discloses Example Compound 36 Two synthetic routes are disclosed, as shown below, which are as long as 11 or 15 steps and are complicated to operate.

[0006] Synthesis Route 1:

[0007] Synthesis route 2:

[0008] Currently, this type of compound and its synthesis method are only disclosed in patent application WO2020259668A1, so there is a need to develop more synthesis methods for this type of compound.

[0009] Summary of the Invention

[0010] The inventors found that the two routes for synthesizing compound 36 in patent application WO2020259668A1 both adopted the steps of first synthesizing the pyridone ring and then synthesizing the imidazole ring to complete the synthesis of the compound. However, the pyridone ring has many active sites, which will participate in the reaction of synthesizing imidazole and fluoroimidazole to produce related by-products, affecting the results of the reaction, resulting in a long synthesis route, cumbersome steps, and low yield.

[0011] Based on the discovery of this problem, the present invention proposes a new synthesis method, namely, a strategy of first synthesizing the imidazole ring and then synthesizing the 2-pyridone heterocycle to synthesize compound 36 and its analogues, which simplifies the operation steps and improves the yield. In addition, the intermediates used in this route are also proposed by the inventors for the first time.

[0012] In the first aspect of the present invention, the present invention provides a method for preparing a compound represented by formula (I-10) or an optical isomer thereof, characterized in that the compound represented by formula (I-8) is contacted with the compound represented by formula (I-9) to obtain the compound represented by formula (I-10) or an optical isomer thereof,

[0013] Wherein, R5 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R6 is independently selected from F, Cl and Br.

[0014] In some embodiments of the present invention, the compound represented by formula (I-10) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0015] In some embodiments of the present invention, the compound represented by formula (I-10) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0016] In some embodiments of the present invention, the compound represented by formula (I-8) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0017] In some embodiments of the present invention, the compound represented by formula (I-8) or its optical isomers are selected from

[0018] In some embodiments of the present invention, the contacting is carried out in at least one solvent selected from tetrahydrofuran, water, toluene, ethanol, dioxane, DMF, and DMSO.

[0019] In some embodiments of the present invention, the contacting is carried out in a mixed solvent of tetrahydrofuran and water.

[0020] In some embodiments of the present invention, the contacting is carried out in the presence of one or more of potassium bicarbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium fluoride, and cesium fluoride.

[0021] In some embodiments of the present invention, the contacting is carried out in the presence of potassium bicarbonate.

[0022] In some embodiments of the present invention, the contacting is carried out under the condition that the catalyst is a palladium catalyst.

[0023] In some embodiments of the present invention, the palladium catalyst is selected from one or more of bisacetonitrile palladium dichloride, Pd(OAc)2 or Pd(DPEPhos)Cl2.

[0024] In some embodiments of the present invention, the palladium catalyst is selected from bisacetonitrile palladium dichloride.

[0025] In some embodiments of the present invention, the contacting is carried out under the condition that the ligand is one or more of bis(2-diphenylphosphinophenyl)ether, dppf, dippf, Ad2nBuP, dtbpf, BI-DIME, and AmgenPhos.

[0026] In some embodiments of the present invention, the contacting is performed under the condition that the ligand is bis(2-diphenylphosphinophenyl)ether.

[0027] In some embodiments of the present invention, the contacting is carried out at a temperature of 60°C-90°C.

[0028] In some embodiments of the present invention, the contacting is carried out at a temperature of 60° C. to 90° C. for 16 hours.

[0029] In some embodiments of the present invention, the contacting is carried out at a temperature of 60° C. for 16 hours.

[0030] In another aspect of the present invention, the present invention provides a compound represented by formula (I-8) or an optical isomer thereof,

[0031] wherein R5 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; and R6 is independently selected from F, Cl, and Br. The inventors have discovered that this compound is a key intermediate in the synthesis of the compound represented by formula (I-10). The introduction of this intermediate simplifies the method for synthesizing the compound represented by formula (I-10) and increases the yield.

[0032] In another aspect of the present invention, the present invention provides a compound represented by formula (I-7) or formula (I-7a) or an optical isomer thereof,

[0033] Wherein, R5 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; and R6 is independently selected from F, Cl, and Br. The inventors have discovered that these two compounds are also key intermediates in the synthesis of the compound represented by formula (I-10). Introducing one of these two key intermediates makes the method for synthesizing the compound represented by formula (I-10) simpler to operate and has a higher yield.

[0034] In some embodiments of the present invention, the compound represented by formula (I-7) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0035] In some embodiments of the present invention, the compound represented by formula (I-7a-a) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0036] In some embodiments of the present invention, the compound represented by formula (I-7) or its optical isomers are selected from

[0037] In some embodiments of the present invention, the compound represented by formula (I-7a) or its optical isomers are selected from

[0038] In another aspect of the present invention, the present invention provides a compound represented by formula (I-6) or an optical isomer thereof,

[0039] wherein R2, R4, and R5 are independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; R3 are independently selected from methyl, ethyl, isopropyl, tert-butyl, and benzyl; and R6 are independently selected from F, Cl, and Br. The inventors have discovered that this compound is also a key intermediate in the synthesis of the compound represented by formula (I-10). The introduction of this intermediate makes the method for synthesizing the compound represented by formula (I-10) simpler to operate and has a higher yield.

[0040] In some embodiments of the present invention, the compound represented by formula (I-6) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0041] In some embodiments of the present invention, the compound represented by formula (I-6) or its optical isomers are selected from

[0042] In another aspect of the present invention, the present invention provides a compound represented by formula (I-5) or an optical isomer thereof,

[0043] wherein R2, R4, and R5 are independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; and R6 are independently selected from F, Cl, and Br. The inventors have discovered that this compound is also a key intermediate in the synthesis of the compound represented by formula (I-10). The introduction of this intermediate simplifies the method for synthesizing the compound represented by formula (I-10) and increases the yield.

[0044] In some embodiments of the present invention, the compound represented by formula (I-5) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0045] In some embodiments of the present invention, the compound represented by formula (I-5) or its optical isomers are selected from

[0046] In another aspect of the present invention, the present invention provides a compound represented by formula (I-4) or an optical isomer thereof,

[0047] wherein R2, R4, and R5 are independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl.

[0048] In some embodiments of the present invention, the compound represented by formula (I-4) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0049] In some embodiments of the present invention, the compound represented by formula (I-4) or its optical isomers are selected from

[0050] In another aspect of the present invention, the present invention provides a compound represented by formula (I-2) or an optical isomer thereof,

[0051] wherein R1 is independently selected from H, Cl, and Br; and R2 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl. The inventors have discovered that this compound is also a key intermediate in the synthesis of the compound represented by formula (I-10). The introduction of this intermediate simplifies the method for synthesizing the compound represented by formula (I-10) and increases yield.

[0052] In some embodiments of the present invention, the compound represented by formula (I-2) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0053] In some embodiments of the present invention, the compound represented by formula (I-2) or its optical isomers are selected from

[0054] In another aspect of the present invention, the present invention provides a compound represented by formula (I-1) or an optical isomer thereof,

[0055] wherein R1 is independently selected from H, Cl, and Br; and R2 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl. The inventors have discovered that this compound is also a key intermediate in the synthesis of the compound represented by formula (I-10). The introduction of this intermediate simplifies the method for synthesizing the compound represented by formula (I-10) and increases yield.

[0056] In some embodiments of the present invention, the compound represented by formula (I-1) or its optical isomers are selected from

[0057] In some embodiments of the present invention, the compound represented by formula (I-1) or its optical isomers are selected from

[0058] In another aspect of the present invention, the present invention also provides a method for preparing a compound represented by formula (I-10) or an optical isomer thereof, characterized in that it comprises: using one or more compounds represented by formula (I-8) or a compound represented by formula (I-7), a compound represented by formula (I-7a), a compound represented by formula (I-6), a compound represented by formula (I-5), a compound represented by formula (I-4), a compound represented by formula (I-2) or a compound represented by formula (I-1) as an intermediate,

[0059] wherein R1 is independently selected from H, Cl, and Br; R2, R4, and R5 are independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; R3 is independently selected from methyl, ethyl, isopropyl, tert-butyl, and benzyl; and R6 is independently selected from F, Cl, and Br. The inventors have discovered that the compound represented by formula (I-8), the compound represented by formula (I-7), the compound represented by formula (I-6), the compound represented by formula (I-5), the compound represented by formula (I-4), the compound represented by formula (I-2), or the compound represented by formula (I-1) are all key intermediates for synthesizing the compound represented by formula (I-10). By using any of these key intermediates, the synthesis method of the compound represented by formula (I-10) can be improved, its operation can be simplified, and the yield can be increased.

[0060] In some embodiments of the present invention, the compound represented by formula (I-8) is prepared by the following method, comprising: subjecting the compound represented by formula (I-7a) to a borylation reaction.

[0061] In some embodiments of the present invention, the borylation reaction is carried out in a solvent of tert-amyl alcohol, DMSO, DMF, tetrahydrofuran, toluene or dioxane.

[0062] In some embodiments of the present invention, the borylation reaction is carried out in the presence of a palladium catalyst and a ligand.

[0063] In some embodiments of the present invention, the palladium catalyst is selected from allylpalladium chloride dimer.

[0064] In some embodiments of the present invention, the ligand is selected from one or more of diphenyl tert-butyl phosphine, (o-anisyl) 3 P or Ph 2 PCy.

[0065] In some embodiments of the present invention, the borylation reaction is carried out in the presence of BisB(pin).

[0066] In some embodiments of the present invention, the borylation reaction is carried out at a temperature of 70°C-90°C.

[0067] In some embodiments of the present invention, the borylation reaction is carried out at a temperature of 70° C.-90° C. for 16 hours.

[0068] In some embodiments of the present invention, the borylation reaction is carried out at a temperature of 70° C. for 16 hours.

[0069] In some embodiments of the present invention, the compound represented by formula (I-7a) is prepared by the following method, comprising: subjecting the compound represented by formula (I-7) to a sulfonylation reaction.

[0070] In some embodiments of the present invention, the sulfonylation reaction is carried out in the presence of p-toluenesulfonyl chloride.

[0071] In some embodiments of the present invention, the compound represented by formula (I-7) is prepared by the following method, comprising: subjecting the compound represented by formula (I-6) to a ring-closure reaction. It should be noted that the ring-closure reaction here is performed after deprotecting the compound represented by formula (I-6) and then performing the ring-closure reaction.

[0072] In some embodiments of the present invention, the ring-closure reaction is carried out in a solvent of dichloromethane, tetrahydrofuran, toluene or acetonitrile.

[0073] In some embodiments of the present invention, the ring-closure reaction is prepared by a three-step reaction, wherein the first step is carried out in the presence of an acidic substance, wherein the acidic substance is selected from trifluoroacetic acid, methanol hydrochloride, dioxane hydrochloride, aqueous hydrochloric acid, trimethylsilyl trifluoromethanesulfonate, trifluoromethanesulfonic acid and zinc bromide.

[0074] In some embodiments of the present invention, the pH of the second step of the ring-closure reaction is 12, wherein the pH is adjusted by lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate or cesium carbonate. In some embodiments of the present invention, the compound represented by formula (I-6) is prepared by the following method, comprising: subjecting the compound represented by formula (I-5) to a ring-opening reaction. It should be noted that the ring-opening reaction here is achieved by attacking the lactam ring with a carbanion.

[0075] In some embodiments of the present invention, the ring-opening reaction is carried out in anhydrous tetrahydrofuran as the solvent.

[0076] In some embodiments of the present invention, the ring-opening reaction is carried out in the presence of an ester substance.

[0077] In some embodiments of the present invention, the ratio of the compound represented by formula (I-5) to the ester substance is 1:(2-10).

[0078] In some embodiments of the present invention, the ester material is selected from isopropyl acetoacetate, methyl acetoacetate, ethyl acetoacetate, tert-butyl acetoacetate and benzyl acetoacetate.

[0079] In some embodiments of the present invention, the ring-opening reaction is carried out in an alkaline solution, and the alkaline solution is prepared by the following steps: dissolving diisopropylamine in anhydrous tetrahydrofuran, cooling to -30 to -40°C, and adding dropwise a substance selected from n-butyllithium, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide or potassium bistrimethylsilylamide, wherein the molar ratio of diisopropylamine to n-butyllithium, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide or potassium bistrimethylsilylamide is 1:(4-20).

[0080] In some embodiments of the present invention, the molar ratio of the compound represented by formula (I-5) to diisopropylamine is 1:12.

[0081] In some embodiments of the present invention, the compound represented by formula (I-5) is prepared by the following method, comprising: subjecting the compound represented by formula (I-4) to a halogenation reaction.

[0082] In some embodiments of the present invention, the halogenation reaction is carried out in a solvent of dichloromethane, acetonitrile or tetrahydrofuran.

[0083] In some embodiments of the present invention, the halogenation reaction is carried out at room temperature for 16-24 hours.

[0084] In some embodiments of the present invention, the halogenation reaction is carried out in the presence of a base such as pyridine, triethylamine or DIPEA.

[0085] In some embodiments of the present invention, the halogenation reaction is carried out in the presence of selectFluor.

[0086] In some embodiments of the present invention, the molar ratio of the compound represented by formula (I-4) to selectFluor is 1:(1.5-4.0).

[0087] In some embodiments of the present invention, the compound represented by formula (I-4) is prepared by the following method, comprising: subjecting the compound represented by formula (I-2) to a ring-closure reaction.

[0088] In some embodiments of the present invention, the ring-closure reaction is carried out in a solvent such as DMF, DMSO or NMP.

[0089] In some embodiments of the present invention, the ring-closure reaction is performed through a first step reaction and a second step reaction.

[0090] In some embodiments of the present invention, the first step reaction is carried out under alkaline conditions.

[0091] In some embodiments of the present invention, the basic conditions are provided by triethylamine, pyridine or DIPEA.

[0092] In some embodiments of the present invention, the first step reaction is carried out at a temperature of 0°C to 50°C.

[0093] In some embodiments of the present invention, the second step reaction is carried out after the first step reaction is completed, and the completion is marked by the disappearance of the compound represented by formula (I-2).

[0094] In some embodiments of the present invention, the second step reaction is carried out in the presence of Lewis acid.

[0095] In some embodiments of the present invention, the Lewis acid is selected from cuprous iodide, cupric bromide, cuprous bromide, ferric chloride, copper acetate and copper trifluoroacetate.

[0096] In some embodiments of the present invention, the second step reaction is carried out under the conditions of 1,10-phenanthroline.

[0097] In some embodiments of the present invention, the second step reaction is carried out in the presence of an oxidizing agent.

[0098] In some embodiments of the present invention, the oxidizing agent is selected from iodine acetate, elemental iodine, NBS, iodobenzene trifluoroacetate and IBX.

[0099] In some embodiments of the present invention, the second step reaction is carried out at a temperature of 0°C to 60°C.

[0100] In some embodiments of the present invention, the compound represented by the above formula (I-2) is prepared by the following method, comprising: subjecting the compound represented by the formula (I-1) to a dehydration reaction.

[0101] In some embodiments of the present invention, the compound represented by formula (I-3) is selected from

[0102] In some embodiments of the present invention, the compound represented by formula (I-3) is selected from

[0103] In some embodiments of the present invention, the dehydration reaction is carried out in a solvent of dichloromethane, acetonitrile, tetrahydrofuran, chloroform or methyl tert-butyl ether.

[0104] In some embodiments of the present invention, the dehydration reaction is carried out in the presence of an organic base.

[0105] In some embodiments of the present invention, the organic base is selected from triethylamine, pyridine and DIPEA.

[0106] In some embodiments of the present invention, the molar ratio of the compound represented by the above formula (I-1) to the organic base is 1:(1.2-4.0), for example, 1:1.2, 1:1.5, 1:1.8, 1:2.0, 1:1.2, 1:2.5, 1:2.8, 1:3.0, 1:3.2, 1:3.5, 1:3.8, 1:4.0, etc.

[0107] In some embodiments of the present invention, the above dehydration reaction is carried out under conditions of acid chloride or acid anhydride.

[0108] In some embodiments of the present invention, the acyl chloride is selected from methanesulfonyl chloride.

[0109] In some embodiments of the present invention, the acid anhydride is selected from methanesulfonic anhydride or trifluoromethanesulfonic anhydride.

[0110] In some embodiments of the present invention, the dehydration reaction is carried out at a temperature of 0 to -60°C, such as 0°C, -10°C, -20°C, -30°C, -40°C, -50°C or -60°C.

[0111] In another aspect of the present invention, the present invention also proposes the use of the compound shown in the aforementioned formula (I-8) or its optical isomer, or the compound shown in the aforementioned formula (I-7) or the compound shown in the aforementioned formula (I-7a) or its optical isomer, or the compound shown in the aforementioned formula (I-6) or its optical isomer, or the compound shown in the aforementioned formula (I-5) or its optical isomer, or the compound shown in the aforementioned formula (I-4) or its optical isomer, or the compound shown in the aforementioned formula (I-2) or its optical isomer, or the compound shown in the aforementioned formula (I-1) or its optical isomer in the preparation of the compound shown in formula (I-10). The inventors have found that the introduction of at least one of these key intermediates can simplify the operation of preparing the compound shown in formula (I-10), improve its yield, etc.

[0112] In another aspect of the present invention, the present invention also proposes a method for preparing a compound of formula (I-10-a) or an optical isomer thereof, characterized in that it comprises: obtaining a compound of formula (I-8-a) or a compound of formula (I-7-a) or a compound of formula (I-7a-a) or a compound of formula (I-6-a) or a compound of formula (I-5-a) or a compound of formula (I-4-a) or a compound of formula (I-2-a) or a compound of formula (I-1-a), Wherein, R1 is independently selected from H, Cl and Br; R2, R4, R5 are independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R3 is independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; R6 is independently selected from F, Cl and Br. The inventors found that the compound represented by formula (I-8-a) or the compound represented by formula (I-7-a) or the compound represented by formula (I-7a-a) or the compound represented by formula (I-6-a) or the compound represented by formula (I-5-a) or the compound represented by formula (I-4-a) or the compound represented by formula (I-2-a) or the compound represented by formula (I-1-a) is a key intermediate in the preparation of the compound represented by formula (I-10-a). The introduction of one of them can make the present invention simple to operate, high in yield, and can control the configuration of the reactants in the reaction to avoid racemization of the chiral intermediate.

[0113] In another aspect of the present invention, the present invention also proposes the use of a compound represented by formula (I-8-a) or its optical isomer, or a compound represented by formula (I-7-a) or its optical isomer, or a compound represented by formula (I-7a-a) or its optical isomer, or a compound represented by formula (I-6-a) or its optical isomer, or a compound represented by formula (I-5-a) or its optical isomer, or a compound represented by formula (I-4-a) or its optical isomer, or a compound represented by formula (I-2-a) or its optical isomer, or a compound represented by formula (I-1-a) or its optical isomer in the preparation of a compound represented by formula (I-10-a). The inventors have discovered that the compound represented by formula (I-8-a) or the compound represented by formula (I-7-a) or the compound represented by formula (I-7a-a) or the compound represented by formula (I-6-a) or the compound represented by formula (I-5-a) or the compound represented by formula (I-4-a) or the compound represented by formula (I-2-a) or the compound represented by formula (I-1-a) is a key intermediate in the preparation of the compound represented by formula (I-10-a). The introduction of one of them can make the operation of the present invention simple, the yield is high, and the configuration of the reactants in the reaction can be controlled to avoid racemization of the chiral intermediate.

[0114] In some embodiments of the present invention, the present invention provides a method for preparing a compound represented by formula (I-10),

[0115] The inventors have found that this route, which involves synthesizing the imidazole ring first and then the 2-pyridone heterocycle, produces fewer by-products, is simple to operate, and has a high yield when preparing compound (I-10).

[0116] In some embodiments of the present invention, the present invention provides a method for preparing a compound represented by formula (I-10-a),

[0117] , the remaining variables are as defined in the present invention. The inventors have found that this route, when preparing compound (I-10-a), adopts the synthesis steps of first synthesizing the imidazole ring and then synthesizing the 2-pyridone heterocycle. The overall process has few by-products, simple operation, high yield, and at the same time.

[0118] In some embodiments of the present invention, the present invention provides a method for preparing compound 36,

[0119] The intermediates of this route can avoid the racemization of the chiral center, and the overall operation is simple and the yield is high.

[0120] The present invention also provides a method for preparing a compound represented by formula (I-10) or an optical isomer thereof, characterized in that the compound represented by formula (I-7a) or an optical isomer thereof is contacted with a compound represented by formula (I-11) to obtain the compound represented by formula (I-10) or an optical isomer thereof.

[0121] in,

[0122] R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl;

[0123] R6 is independently selected from Cl and Br, and the other variables are as defined above.

[0124] In some embodiments of the present invention, the compound represented by formula (I-10) or its optical isomer is prepared by reacting the compound represented by formula (I-7a) or its optical isomer with the compound represented by formula (I-11) using one or more of tetrahydrofuran and water as solvents.

[0125] In some embodiments of the present invention, the compound represented by formula (I-7a) or its optical isomer is reacted with the compound represented by formula (I-11) under the conditions of one or more of potassium bicarbonate, potassium carbonate, potassium acetate, sodium carbonate, sodium bicarbonate, and potassium fluoride as a base.

[0126] In some embodiments of the present invention, the reaction of the compound represented by formula (I-7a) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of Pd(OAc)2, Pd(MeCN)2Cl2, [PdCl(C3H5)]2, Pd(TFA)2, and [(cinnamyl)PdCl]2 as a catalyst.

[0127] In some embodiments of the present invention, the reaction of the compound represented by formula (I-7a) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of dppb, dippf, BI-DIME, XantPhos, and DPEPhos as ligands.

[0128] In some embodiments of the present invention, the reaction of the compound represented by formula (I-7a) or its optical isomer with the compound represented by formula (I-11) is carried out at 45°C-75°C.

[0129] In some embodiments of the present invention, the present invention provides another method for preparing compound 36,

[0130] In some embodiments of the present invention, the compound 36 or its optical isomer is prepared by reacting the compound of formula (7a) or its optical isomer with compound (I-11) in one or more of tetrahydrofuran and water as solvent.

[0131] In some embodiments of the present invention, the compound (7a) or its optical isomer is reacted with the compound represented by formula (I-11) in the presence of one or more of potassium bicarbonate, potassium carbonate, potassium acetate, sodium carbonate, sodium bicarbonate, and potassium fluoride as a base.

[0132] In some embodiments of the present invention, the reaction of the compound (7a) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of using one or more of Pd(OAc)2, Pd(MeCN)2Cl2, [PdCl(C3H5)]2, Pd(TFA)2, and [(cinnamyl)PdCl]2 as catalysts.

[0133] In some embodiments of the present invention, the reaction of the compound (7a) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of dppb, dippf, BI-DIME, XantPhos, and DPEPhos as ligands.

[0134] In some embodiments of the present invention, the reaction of the compound (7a) or its optical isomer with the compound represented by formula (I-11) is carried out at 45°C-75°C.

[0135] In some embodiments of the present invention, the present invention provides a method for preparing a compound represented by formula (I-10),

[0136] The remaining variables are as defined herein. The inventors have discovered that this route, which employs the synthesis steps of first synthesizing the imidazole ring and then synthesizing the 2-pyridone heterocycle, produces few by-products, is simple to operate, and yields high. Furthermore, this reduces the loss of expensive raw materials and lowers synthesis costs.

[0137] In some embodiments of the present invention, the present invention provides a method for preparing a compound represented by formula (I-10-a),

[0138] , and the remaining variables are as defined herein. The inventors have discovered that this route, when preparing compound (I-10-a), employs a synthesis step of first synthesizing the imidazole ring and then synthesizing the 2-pyridone heterocycle. This overall process produces few by-products, is simple to operate, and has a high yield. Furthermore, this reduces the loss of expensive raw materials and lowers synthesis costs.

[0139] In some embodiments of the present invention, the present invention provides a method for preparing compound 36,

[0140] The intermediates of this route can avoid the racemization of the chiral center, reduce the proportion of by-products generated, simplify the reaction route, and have simple overall operations and high yields.

[0141] In another aspect of the present invention, the present invention provides a compound represented by formula (I-11) and formula (III-3) or an optical isomer thereof,

[0142] In some embodiments of the present invention, the compound represented by formula (I-11) is prepared by the following method, comprising: subjecting the compound represented by formula (III-3) to a tetrazole ring-closure reaction.

[0143] In some embodiments of the present invention, the compound represented by formula (I-11) is prepared by the following method, comprising: subjecting the compound represented by formula (III-3) to a tetrazole ring-closure reaction with triethyl orthoformate and azide.

[0144] In some embodiments of the present invention, the compound represented by formula (I-11) is prepared by the following method, comprising: subjecting the compound represented by formula (III-3), triethyl orthoformate and azide to a tetrazole ring-closure reaction using glacial acetic acid as a solvent.

[0145] In some embodiments of the present invention, the azide is selected from azide reagents such as NaN3, tributyltin azide or TMS-N3.

[0146] In some embodiments of the present invention, the compound represented by formula (III-3) is reacted with triethyl orthoformate and azide at 15°C-25°C.

[0147] In some embodiments of the present invention, the reaction time of the compound represented by formula (III-3), triethyl orthoformate and azide is 3 hours to 5 hours.

[0148] In some embodiments of the present invention, the compound represented by formula (I-11) can also be prepared by the following method, comprising: first reacting the compound represented by formula (III-3) with formic acid and acetic anhydride, then adding pyridine and DPPA to react, and finally obtaining the compound represented by formula (I-11).

[0149] In some embodiments of the present invention, the compound represented by formula (III-3) is prepared by the following method, comprising: reacting compound (III-1) with compound (III-2) through Miyaura borylation reaction.

[0150] In some embodiments of the present invention, the Miyaura borylation reaction is carried out using one or more of potassium acetate, potassium carbonate or potassium bicarbonate as a base.

[0151] In some embodiments of the present invention, the Miyaura borylation reaction is carried out in the presence of one or more of dioxane, DMSO, DMF, tert-amyl alcohol, toluene, and tetrahydrofuran as a solvent.

[0152] In some embodiments of the present invention, the Miyaura borylation reaction is catalyzed by one or more of PdCl2(dppf), palladium acetate, or allylpalladium chloride dimer.

[0153] In some embodiments of the present invention, the Miyaura borylation reaction is carried out at 75°C-90°C.

[0154] In some embodiments of the present invention, the Miyaura borylation reaction is carried out at 80°C-85°C.

[0155] In some embodiments of the present invention, the compound represented by formula (III-3) is also prepared by the following method, comprising: reacting compound (III-4) with compound (III-2) through CH activated borylation reaction to obtain the compound.

[0156] In some embodiments of the present invention, the CH activated borylation reaction is carried out in the presence of one or more of cyclopentyl methyl ether, dioxane, DMSO, DMF, tert-amyl alcohol, toluene, and tetrahydrofuran as a solvent.

[0157] In some embodiments of the present invention, the CH activated borylation reaction is catalyzed by one or more of [Ir(OMe)(cod)]2, PdCl2(dppf), palladium acetate or allylpalladium chloride dimer.

[0158] In some embodiments of the present invention, the CH activated borylation reaction uses one or both of Tmphen and 1,10-phenanthroline as ligands.

[0159] In some embodiments of the present invention, the C—H activated borylation reaction is carried out at 75° C.-90° C.

[0160] In some embodiments of the present invention, the C—H activated borylation reaction is carried out at 80° C.-85° C.

[0161] In the first aspect of the present invention, the present invention provides a method for preparing a compound represented by formula (II-10) or an optical isomer thereof, characterized in that the compound represented by formula (II-8) is contacted with the compound represented by formula (I-9) to obtain the compound represented by formula (II-10) or an optical isomer thereof,

[0162] , where R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 6a are independently selected from F, Cl and Br.

[0163] In some embodiments of the present invention, the compound represented by formula (II-10) or its optical isomers are selected from The remaining variables are as defined in the present invention.

[0164] In some embodiments of the present invention, the compound represented by formula (II-8) or its optical isomers are selected from

[0165] In some embodiments of the present invention, the contacting is carried out in at least one solvent selected from tetrahydrofuran, water, toluene, ethanol, dioxane, DMF, and DMSO.

[0166] In some embodiments of the present invention, the contacting is carried out in a solvent which is a mixed solvent of tetrahydrofuran and water.

[0167] In some embodiments of the present invention, the contacting is carried out in the presence of one or more of potassium bicarbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium fluoride, and cesium fluoride.

[0168] In some embodiments of the present invention, the contacting is carried out in the presence of potassium bicarbonate.

[0169] In some embodiments of the present invention, the contacting is carried out under the condition that the catalyst is a palladium catalyst.

[0170] In some embodiments of the present invention, the palladium catalyst is selected from one or more of bisacetonitrile palladium dichloride, Pd(OAc)2 or Pd(DPEPhos)Cl2.

[0171] In some embodiments of the present invention, the palladium catalyst is selected from bisacetonitrile palladium dichloride.

[0172] In some embodiments of the present invention, the above-mentioned contact is carried out under the conditions that the ligand is one or more of bis(2-diphenylphosphinophenyl) ether, dppf, dippf, DPEPhos, Ad2nBuP, dtbpf, BI-DIME, and AmgenPhos.

[0173] In some embodiments of the present invention, the contacting is performed under the condition that the ligand is bis(2-diphenylphosphinophenyl)ether.

[0174] In some embodiments of the present invention, the contacting is carried out at a temperature of 60°C-90°C.

[0175] In some embodiments of the present invention, the contacting is carried out at a temperature of 60° C. to 90° C. for 16 hours.

[0176] In some embodiments of the present invention, the contacting is carried out at a temperature of 60° C. for 16 hours.

[0177] In another aspect of the present invention, the present invention provides a compound represented by formula (II-8) or an optical isomer thereof,

[0178] Among them, R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 6a They are independently selected from F, Cl and Br. The inventors found that this compound is a key intermediate in the synthesis of the compound represented by formula (II-10). The introduction of this intermediate makes the method for synthesizing the compound represented by formula (II-10) simpler to operate and has a higher yield.

[0179] In another aspect of the present invention, the present invention provides a compound represented by formula (II-7) or formula (II-7a) or an optical isomer thereof,

[0180] Among them, R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl;6a They are independently selected from F, Cl and Br. The inventors have found that these two compounds are also key intermediates in the synthesis of the compound represented by formula (II-10). The introduction of one of these two key intermediates makes the method for synthesizing the compound represented by formula (II-10) simpler to operate and has a higher yield.

[0181] In some embodiments of the present invention, the compound represented by formula (II-7) or its optical isomers are selected from

[0182] In some embodiments of the present invention, the compound represented by formula (II-7a) or its optical isomers are selected from

[0183] In another aspect of the present invention, the present invention provides a compound represented by formula (II-6) or an optical isomer thereof,

[0184] Among them, R 2a 、R 4a 、R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 3a R are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; 6a They are independently selected from F, Cl and Br. The inventors found that this compound is also a key intermediate in the synthesis of the compound represented by formula (II-10). The introduction of this intermediate makes the method for synthesizing the compound represented by formula (II-10) simpler to operate and has a higher yield.

[0185] In some embodiments of the present invention, the compound represented by formula (II-6) or its optical isomers are selected from

[0186] In another aspect of the present invention, the present invention provides a compound represented by formula (II-5) or an optical isomer thereof,

[0187] Among them, R 2a 、R 4a 、R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 6a They are independently selected from F, Cl and Br. The inventors found that this compound is also a key intermediate in the synthesis of the compound represented by formula (II-10). The introduction of this intermediate makes the method for synthesizing the compound represented by formula (II-10) simpler to operate and has a higher yield.

[0188] In some embodiments of the present invention, the compound represented by formula (II-5) or its optical isomers are selected from

[0189] In another aspect of the present invention, the present invention provides a compound represented by formula (II-4) or an optical isomer thereof,

[0190] Among them, R 2a 、R 4a 、R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl.

[0191] In some embodiments of the present invention, the compound represented by formula (II-4) or its optical isomers are selected from

[0192] In another aspect of the present invention, the present invention provides a compound represented by formula (II-2) or an optical isomer thereof,

[0193] Among them, R 1a are independently selected from H, Cl and Br; R 2a Each of the compounds is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl. The inventors have discovered that this compound is also a key intermediate in the synthesis of the compound represented by formula (II-10). The introduction of this intermediate makes the method for synthesizing the compound represented by formula (II-10) simpler to operate and has a higher yield.

[0194] In some embodiments of the present invention, the compound represented by formula (II-2) or its optical isomers are selected from

[0195] In another aspect of the present invention, the present invention provides a compound represented by formula (II-1) or an optical isomer thereof,

[0196] Among them, R 1a are independently selected from H, Cl and Br; R 2a Each of the compounds is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl. The inventors have discovered that this compound is also a key intermediate in the synthesis of the compound represented by formula (II-10). The introduction of this intermediate makes the method for synthesizing the compound represented by formula (II-10) simpler to operate and has a higher yield.

[0197] In some embodiments of the present invention, the compound represented by formula (II-1) or its optical isomers are selected from

[0198] In another aspect of the present invention, the present invention also provides a method for preparing a compound represented by formula (II-10) or an optical isomer thereof, characterized in that it comprises: using one or more compounds represented by formula (II-8) or a compound represented by formula (II-7), a compound represented by formula (II-7a), a compound represented by formula (II-6), a compound represented by formula (II-5), a compound represented by formula (II-4), a compound represented by formula (II-2) or a compound represented by formula (II-1) as an intermediate,

[0199] Among them, R 1a are independently selected from H, Cl and Br; R 2a 、R 4a 、R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 3a R are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; 6a are independently selected from F, Cl and Br. The inventors have found that the compound represented by formula (II-8) or the compound represented by formula (II-7) or the compound represented by formula (II-6) or the compound represented by formula (II-5) or the compound represented by formula (II-4) or the compound represented by formula (II-2) or the compound represented by formula (II-1) are all key intermediates for synthesizing the compound represented by formula (II-10). By using one of these key intermediates, the synthesis method of the compound represented by formula (II-10) can be improved, its operation can be simplified, and the yield can be increased.

[0200] In some embodiments of the present invention, the compound represented by formula (II-8) is prepared by the following method, comprising: subjecting the compound represented by formula (II-7a) to a borylation reaction.

[0201] In some embodiments of the present invention, the borylation reaction is carried out in a solvent of tert-amyl alcohol, DMSO, DMF, tetrahydrofuran, toluene or dioxane.

[0202] In some embodiments of the present invention, the borylation reaction is carried out in the presence of a palladium catalyst and a ligand.

[0203] In some embodiments of the present invention, the ligand is selected from one or more of diphenyl tert-butyl phosphine, (o-anisyl) 3 P or Ph 2 PCy.

[0204] In some embodiments of the present invention, the borylation reaction is carried out in the presence of BisB(pin).

[0205] In some embodiments of the present invention, the borylation reaction is carried out at a temperature of 70°C-90°C.

[0206] In some embodiments of the present invention, the borylation reaction is carried out at a temperature of 70° C.-90° C. for 16 hours.

[0207] In some embodiments of the present invention, the borylation reaction is carried out at a temperature of 70° C. for 16 hours.

[0208] In some embodiments of the present invention, the compound represented by formula (II-7a) is prepared by the following method, comprising: subjecting the compound represented by formula (II-7) to a sulfonylation reaction.

[0209] In some embodiments of the present invention, the sulfonylation reaction is carried out in the presence of p-toluenesulfonyl chloride.

[0210] In some embodiments of the present invention, the compound represented by formula (II-7) is prepared by the following method, comprising:

[0211] It should be noted that the ring-closing reaction here is performed by first deprotecting the compound represented by formula (II-6) and then performing the ring-closing reaction.

[0212] In some embodiments of the present invention, the ring-closure reaction is carried out in a solvent of dichloromethane, tetrahydrofuran, toluene or acetonitrile.

[0213] In some embodiments of the present invention, the ring-closure reaction is prepared by a three-step reaction, wherein the first step is carried out in the presence of an acidic substance, wherein the acidic substance is selected from trifluoroacetic acid, methanol hydrochloride, dioxane hydrochloride, aqueous hydrochloric acid, trimethylsilyl trifluoromethanesulfonate, trifluoromethanesulfonic acid and zinc bromide.

[0214] In some embodiments of the present invention, the pH of the second step of the ring-closure reaction is 12, wherein the pH is adjusted by lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate or cesium carbonate. In some embodiments of the present invention, the compound represented by formula (II-6) is prepared by the following method, comprising: subjecting the compound represented by formula (II-5) to a ring-opening reaction. It should be noted that the ring-opening reaction here is achieved by attacking the lactam ring with a carbanion.

[0215] In some embodiments of the present invention, the ring-opening reaction is carried out in anhydrous tetrahydrofuran as the solvent.

[0216] In some embodiments of the present invention, the ring-opening reaction is carried out in the presence of an ester substance.

[0217] In some embodiments of the present invention, the ratio of the compound represented by formula (II-5) to the ester substance is 1:(2-10).

[0218] In some embodiments of the present invention, the ester material is selected from isopropyl acetoacetate, methyl acetoacetate, ethyl acetoacetate, tert-butyl acetoacetate and benzyl acetoacetate.

[0219] In some embodiments of the present invention, the ring-opening reaction is carried out in an alkaline solution, and the alkaline solution is prepared by the following steps: dissolving diisopropylamine in anhydrous tetrahydrofuran, cooling to -30 to -40°C, and adding dropwise a substance selected from n-butyllithium, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide or potassium bistrimethylsilylamide, wherein the molar ratio of diisopropylamine to n-butyllithium, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide or potassium bistrimethylsilylamide is 1:(4-20).

[0220] In some embodiments of the present invention, the molar ratio of the compound represented by formula (II-5) to diisopropylamine is 1:12.

[0221] In some embodiments of the present invention, the compound represented by formula (II-5) is prepared by the following method, comprising: subjecting the compound represented by formula (II-4) to a halogenation reaction.

[0222] In some embodiments of the present invention, the halogenation reaction is carried out in a solvent of dichloromethane, acetonitrile or tetrahydrofuran.

[0223] In some embodiments of the present invention, the halogenation reaction is carried out at room temperature for 16-24 hours.

[0224] In some embodiments of the present invention, the halogenation reaction is carried out in the presence of a base such as pyridine, triethylamine or DIPEA.

[0225] In some embodiments of the present invention, the halogenation reaction is carried out in the presence of selectFluor.

[0226] In some embodiments of the present invention, the molar ratio of the compound represented by formula (II-4) to selectFluor is 1:(1.5-4.0).

[0227] In some embodiments of the present invention, the compound represented by formula (II-4) is prepared by the following method, comprising: subjecting the compound represented by formula (II-2) to a ring-closure reaction.

[0228] In some embodiments of the present invention, the ring-closure reaction is carried out in a solvent such as DMF, DMSO or NMP.

[0229] In some embodiments of the present invention, the ring-closure reaction is performed through a first step reaction and a second step reaction.

[0230] In some embodiments of the present invention, the first step reaction is carried out under alkaline conditions.

[0231] In some embodiments of the present invention, the basic conditions are provided by triethylamine, pyridine or DIPEA.

[0232] In some embodiments of the present invention, the first step reaction is carried out at a temperature of 0°C to 50°C.

[0233] In some embodiments of the present invention, the second step reaction is carried out after the first step reaction is completed, and the completion is marked by the disappearance of the compound represented by formula (II-2).

[0234] In some embodiments of the present invention, the second step reaction is carried out in the presence of Lewis acid.

[0235] In some embodiments of the present invention, the Lewis acid is selected from cuprous iodide, cupric bromide, cuprous bromide, ferric chloride, copper acetate and copper trifluoroacetate.

[0236] In some embodiments of the present invention, the second step reaction is carried out under the conditions of 1,10-phenanthroline.

[0237] In some embodiments of the present invention, the second step reaction is carried out in the presence of an oxidizing agent.

[0238] In some embodiments of the present invention, the oxidizing agent is selected from iodine acetate, elemental iodine, NBS, iodobenzene trifluoroacetate and IBX.

[0239] In some embodiments of the present invention, the second step reaction is carried out at a temperature of 0°C to 60°C.

[0240] In some embodiments of the present invention, the compound represented by the above formula (II-2) is prepared by the following method, comprising: subjecting the compound represented by the formula (II-1) to a dehydration reaction.

[0241] In some embodiments of the present invention, the dehydration reaction is carried out in a solvent of dichloromethane, acetonitrile, tetrahydrofuran, chloroform or methyl tert-butyl ether.

[0242] In some embodiments of the present invention, the dehydration reaction is carried out in the presence of an organic base.

[0243] In some embodiments of the present invention, the organic base is selected from triethylamine, pyridine and DIPEA.

[0244] In some embodiments of the present invention, the molar ratio of the compound represented by the above formula (II-1) to the organic base is 1:(1.2-4.0), for example, 1:1.2, 1:1.5, 1:1.8, 1:2.0, 1:1.2, 1:2.5, 1:2.8, 1:3.0, 1:3.2, 1:3.5, 1:3.8, 1:4.0, etc.

[0245] In some embodiments of the present invention, the above dehydration reaction is carried out under conditions of acid chloride or acid anhydride.

[0246] In some embodiments of the present invention, the acyl chloride is selected from methanesulfonyl chloride.

[0247] In some embodiments of the present invention, the acid anhydride is selected from methanesulfonic anhydride or trifluoromethanesulfonic anhydride.

[0248] In some embodiments of the present invention, the dehydration reaction is carried out at a temperature of 0 to -60°C, such as 0°C, -10°C, -20°C, -30°C, -40°C, -50°C or -60°C.

[0249] In another aspect of the present invention, the present invention also proposes the use of the compound shown in formula (II-8) or its optical isomer, or the compound shown in formula (II-7) or the compound shown in formula (II-7a) or its optical isomer, or the compound shown in formula (II-6) or its optical isomer, or the compound shown in formula (II-5) or its optical isomer, or the compound shown in formula (II-4) or its optical isomer, or the compound shown in formula (II-2) or its optical isomer, or the compound shown in formula (II-1) or its optical isomer in the preparation of the compound shown in formula (II-10). The inventors have found that the introduction of at least one of these key intermediates can simplify the operation of preparing the compound shown in formula (II-10), improve its yield, etc.

[0250] In some embodiments of the present invention, the present invention provides a method for preparing a compound represented by formula (II-10),

[0251] The inventors have found that this route, which involves synthesizing the imidazole ring first and then the 2-pyridone heterocycle, produces fewer by-products, is simple to operate, and has a high yield when preparing compound (II-10).

[0252] In some embodiments of the present invention, the present invention provides a method for preparing compound 36-B.

[0253] The intermediates of this route can avoid the racemization of the chiral center, and the overall operation is simple and the yield is high.

[0254] The present invention also provides a method for preparing a compound represented by formula (II-10) or an optical isomer thereof, characterized in that the compound represented by formula (II-7a) or an optical isomer thereof is contacted with a compound represented by formula (II-11) to obtain the compound represented by formula (II-10) or an optical isomer thereof.

[0255] in,

[0256] R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl;

[0257] R 6a F, Cl and Br are independently selected, and the other variables are defined as above.

[0258] In some embodiments of the present invention, the compound represented by formula (II-10) or its optical isomer is prepared by reacting the compound represented by formula (II-7a) or its optical isomer with the compound represented by formula (I-11) using one or more of tetrahydrofuran and water as solvents.

[0259] In some embodiments of the present invention, the compound represented by formula (II-7a) or its optical isomer reacts with the compound represented by formula (I-11) under the conditions of one or more of potassium bicarbonate, potassium carbonate, potassium acetate, sodium carbonate, sodium bicarbonate, and potassium fluoride as a base.

[0260] In some embodiments of the present invention, the reaction of the compound represented by formula (II-7a) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of Pd(OAc)2, Pd(MeCN)2Cl2, [PdCl(C3H5)]2, Pd(TFA)2, [(cinnamyl)PdCl]2 as a catalyst.

[0261] In some embodiments of the present invention, the reaction of the compound represented by formula (II-7a) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of dppb, dippf, BI-DIME, XantPhos, and DPEPhos as ligands.

[0262] In some embodiments of the present invention, the reaction of the compound represented by formula (II-7a) or its optical isomer with the compound represented by formula (I-11) is carried out at 45°C-75°C.

[0263] In some embodiments of the present invention, the present invention provides another method for preparing compound 36-B.

[0264] In some embodiments of the present invention, the compound 36-B or its optical isomer is prepared by reacting the compound of formula 36-B or its optical isomer with compound (7a-B) in one or more of tetrahydrofuran and water as solvent.

[0265] In some embodiments of the present invention, the compound represented by formula (7a-B) or its optical isomer is reacted with the compound represented by formula (I-11) under the conditions of one or more of potassium bicarbonate, potassium carbonate, potassium acetate, sodium carbonate, sodium bicarbonate, and potassium fluoride as a base.

[0266] In some embodiments of the present invention, the reaction of the compound represented by formula (7a-B) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of Pd(OAc)2, Pd(MeCN)2Cl2, [PdCl(C3H5)]2, Pd(TFA)2, [(cinnamyl)PdCl]2 as a catalyst.

[0267] In some embodiments of the present invention, the reaction of the compound represented by formula (7a-B) or its optical isomer with the compound represented by formula (I-11) is carried out under the conditions of one or more of dppb, dippf, BI-DIME, XantPhos, and DPEPhos as ligands.

[0268] In some embodiments of the present invention, the reaction of the compound represented by formula (7a-B) or its optical isomer with the compound represented by formula (I-11) is carried out at 45°C-75°C.

[0269] In some embodiments of the present invention, the present invention provides a method for preparing a compound represented by formula (II-10),

[0270] The remaining variables are as defined herein. The inventors have discovered that this route, which employs the synthesis steps of first synthesizing the imidazole ring and then synthesizing the 2-pyridone heterocycle when preparing compound (II-10), avoids racemization of the chiral center during the overall process, reducing the loss of expensive raw materials. Furthermore, the reaction route is streamlined, the overall operation is simple, and the reaction yield is high.

[0271] In some embodiments of the present invention, the present invention provides a method for preparing compound 36-B.

[0272] The intermediates in this route can avoid racemization of the chiral center, reducing the loss of expensive raw materials. Furthermore, the reaction route is streamlined, the overall operation is simple, and the reaction yield is high. In some embodiments of the present invention, the present invention has at least one of the following advantageous technical features compared to the prior art:

[0273] 1) The prior art uses the steps of synthesizing the pyridone ring first and then the imidazole ring to complete the synthesis of the compound. The pyridone ring has many active sites, which will participate in the reaction to produce related by-products in the synthesis of imidazole and fluoroimidazole, affecting the reaction results. The present invention, on the other hand, adopts the synthesis steps of synthesizing the imidazole ring first and then synthesizing the 2-pyridone heterocycle.

[0274] 2) Each intermediate of the present invention is a novel compound designed by the inventors to complete the present invention. Utilizing any one of these intermediates can improve the synthesis process of the compound represented by formula (I-10), increase its yield, simplify the operation, and other effects. 3) The reagents and solvents used in the synthesis of each intermediate and the final product employed in the present invention are all mild and controllable reagents.

[0275] 4) For the synthesis of compound (I-10-a), 35-1 was synthesized from Int-C in the prior art WO2020259668A1. In order to avoid the racemization of the chiral center, high-risk reagents such as trimethylsilylated diazomethane were used to convert the carboxylic acid into a halogenated ethyl ketone group. However, the subsequent reaction with the amidine group (35-1 and Int-V to synthesize 35-2) to synthesize imidazole also caused the chiral center to racemize and the yield was low. In the present invention, the inventors creatively introduced new key intermediates (I-1-a)-(I-8-a) for the first time, which completely avoided the problem of chiral center racemization, greatly simplified the operation, improved the yield, was safer and greener, and was suitable for large-scale industrial production.

[0276] 5) In the synthesis of pyridone, the prior art WO2020259668A1 is to heat and mix the reaction substrate with dimethyl acetone dicarboxylate to react without solvent, and then heat and decarboxylate to obtain the target pyridone ring. The reaction yield is very low and the compatibility of the substrate is very poor. In the present invention, by introducing the compound shown in the key intermediate formula (I-6) in the synthesis, the isopropyl acetoacetate dianion can be used to attack Boc-amide at low temperature, and then the Boc protecting group is removed, and the isopropyl ester group is subsequently hydrolyzed. The product will automatically close the ring to form pyridone, and the introduction of the intermediate makes the reaction conditions of the step of forming pyridine ring ketone mild, the substrate compatibility is high, and the pyridone ring can be obtained with a very high total yield.

[0277] 6) The present invention provides a novel, concise route for synthesizing compound II-10. This route reduces the production of byproducts during the synthesis of compound II-10 and prevents racemization of the chiral center during the synthesis of compound II-10. This simplifies the reaction procedure, improves yield, and is more suitable for large-scale industrial production.

[0278] 7) In the synthesis of compound I-10 and compound II-10, the use of the new route compound (I-11) simplifies the synthesis route, reduces the use of expensive raw materials, and can obtain compound I-10 or compound II-10 in only one coupling reaction, thereby indirectly improving the overall yield of the reaction.

[0279] Definition and Description

[0280] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be construed as indefinite or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.

[0281] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are encompassed within the scope of the present invention.

[0282] The compounds of the present invention may exist in specific forms. Unless otherwise indicated, the term "tautomer" or "tautomeric form" means that at room temperature, different functional group isomers are in dynamic equilibrium and can quickly convert to each other. If tautomerism is possible (such as in solution), the chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (proton tautomers) (also known as prototropic tautomers) include interconversions carried out by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence isomers (valence tautomers) include interconversions carried out by the reorganization of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between the two tautomers of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one.

[0283] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14 C). For example, deuterated drugs can be formed by replacing hydrogen with heavy hydrogen. The bond between deuterium and carbon is stronger than that between ordinary hydrogen and carbon. Compared to undeuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced therapeutic efficacy, and prolonged biological half-life. All isotopic variations of the compounds of this invention, whether radioactive or not, are encompassed by this invention. "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs as well as instances where it does not.

[0284] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permitted only if such combinations result in stable compounds. For example, Can be selected from wait.

[0285] In the present invention, "room temperature" refers to a temperature from about 10° C. to about 40° C. In some embodiments, "room temperature" refers to a temperature from about 20° C. to about 30° C.; in other embodiments, "room temperature" refers to 20° C., 22.5° C., 25° C., 27.5° C., etc.

[0286] In the present invention, "room temperature or under heating conditions" means that the reaction is carried out at a certain temperature, which is room temperature or a specific temperature reached by heating. For example, the reaction of preparing the compound of formula (III) from the compound of formula (IV) is carried out at room temperature or under heating conditions, which means that the reaction is carried out at a certain temperature, which is room temperature or a specific temperature reached by heating; for example, the reaction is carried out at room temperature (e.g., 20°C-30°C) or under heating conditions to 30°C-65°C, that is, the reaction is carried out at 20°C-65°C.

[0287] In the context of the present invention, all numerical values ​​disclosed herein are approximate. The numerical value of each number may vary by 1%, 2%, 5%, 7%, 8%, or 10%. Whenever a number having a value of N is disclosed, any number within the value of N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, or N+ / -10% is expressly disclosed, where "+ / -" means plus or minus. Whenever a lower limit, DL, and an upper limit, DU, are disclosed within a numerical range, any value within the disclosed range is expressly disclosed.

[0288] All reaction steps described in the present invention are subjected to post-processing, such as cooling, collection, extraction, filtration, separation, purification, or a combination thereof, after the reaction reaches a certain level, such as when the raw material consumption is greater than 70%, greater than 80%, greater than 90%, or greater than 95%, or after detection that the raw material has been completely consumed. The reaction level can be detected by conventional methods such as thin layer chromatography (TLC), high performance liquid chromatography (HPLC), gas chromatography (GC), etc. The reaction solution can be post-processed using conventional methods, for example, by evaporating the reaction solvent under reduced pressure or conventional distillation, collecting the crude product, and directly feeding it into the next reaction; or directly filtering the crude product, and directly feeding it into the next reaction; or standing it, decanting the supernatant to obtain the crude product, and directly feeding it into the next reaction; or selecting an appropriate organic solvent or a combination thereof for purification steps such as extraction, distillation, crystallization, column chromatography, rinsing, and beating.

[0289] Regardless of whether the numerical values ​​of the present invention are modified by the term "about", it should be understood that the numerical values ​​are modified by "about". The term "about" is used to modify a numerical value that differs by 10%. In some embodiments, "about" is used to modify a numerical value that differs by 5%. In some embodiments, "about" is used to modify a numerical value that differs by 3%, 2%, or 1%. It is understood that the error range of the numerical value modified by "about" is the actual or reasonable error range of the numerical value modified by it.

[0290] In each step of the reaction process described in the present invention, the reaction raw materials or other reagents can be added to the reaction system by dropwise addition. Each dropwise addition process and each step of the reaction are carried out under certain temperature conditions, and any temperature suitable for use in each dropwise addition process or each reaction process is included in the present invention. In addition, many similar modifications, equivalent replacements, or temperatures and temperature ranges equivalent to those described in the present invention are considered to be included in the present invention. The present invention provides preferred temperatures or temperature ranges for each dropwise addition process, as well as preferred reaction temperatures for each reaction.

[0291] The solvents used in each reaction step described in the present invention are not particularly limited. Any solvent that can dissolve the starting materials to a certain extent and does not inhibit the reaction is included in the present invention. In addition, many similar modifications, equivalent substitutions, or solvents equivalent to those described in the present invention, solvent combinations, and different ratios of solvent combinations in the art are considered to be within the scope of the present invention. The present invention provides preferred solvents for use in each reaction step.

[0292] The products of each reaction step described in the present invention can be purified by recrystallization under appropriate conditions. The recrystallization solvent used is not particularly limited, and any solvent that can dissolve the crude product to a certain extent and can precipitate crystals under certain conditions is included in the present invention. In addition, many similar modifications, equivalent replacements, or solvents equivalent to those described in the present invention, solvent combinations, and different proportions of solvent combinations in the art are considered to be included within the scope of the present invention. Among them, the solvent can be alcohols, ethers, alkanes, halogenated hydrocarbons, esters, ketones, aromatic hydrocarbons, acetonitrile, acetic acid, water, DMF or a combination thereof. For example, water, acetic acid, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, petroleum ether, n-pentane, n-hexane, n-heptane, cyclohexane, DMF, tetrahydrofuran, ethyl ether, isopropyl ether, dioxane, methyl tert-butyl ether, dimethoxyethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, dichloromethane, 1,2-dichloroethane, chloroform, carbon tetrachloride, ethyl acetate, isopropyl acetate, acetone, butanone, benzene, toluene, xylene or a combination thereof.

[0293] The content of water in the solvent of the present invention is not particularly limited, that is, the content of water in the solvent does not affect the occurrence of the reaction of the present invention. Any solvent containing a certain amount of water that can be used in the present invention to a certain extent is considered to be the solvent of the present invention. For example, the content of water in the solvent is approximately less than 0.05%, less than 0.1%, less than 0.2%, less than 0.5%, less than 5%, less than 10%, less than 25%, less than 30%, or 0%. In some embodiments, the water content of the solvent is within a certain range, which is more conducive to the reaction; for example, in the step of using ethanol as the reaction solvent, using anhydrous ethanol is more conducive to the reaction. In some embodiments, the water content of the solvent exceeds a certain range, which may affect the reaction (for example, affecting the yield of the reaction), but does not affect the occurrence of the reaction.

[0294] The intermediate compounds of the present invention can be prepared by various synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining the above with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples of the present invention. All of these should be considered to be within the scope of protection of the present invention.

[0295] The solvent used in the present invention is commercially available.

[0296] The present invention uses the following abbreviations:

[0297] DPEphos stands for bis(2-diphenylphosphinophenyl) ether, Boc stands for tert-butyloxycarbonyl, THP stands for 2-tetrahydropyranyl, CBz stands for benzyloxycarbonyl, Ac stands for acetyl, Bn stands for benzyl, PMB stands for p-methoxybenzyl, MsCl stands for methanesulfonyl chloride, LDA stands for lithium diisopropylamide, TFA stands for trifluoroacetic acid, LiOH stands for lithium hydroxide, Ts stands for p-toluenesulfonyl, DMF stands for N,N-dimethylformamide, DMSO stands for dimethyl sulfoxide, NMP stands for N-methylpyrrolidone, DIPEA stands for N,N-diisopropylethylamine, NBS stands for N-bromosuccinimide, IBX stands for 2-iodoacylbenzoic acid, DCM stands for dichloromethane, heptane stands for n-heptane, selectFluor stands for 1-chloromethyl-4-fluoro-1,4-diazobicyclo-2.2.2-octane bis(tetrafluoroborate), and BisB(pin) stands for pinacol diboronate. , EA represents ethyl acetate, dppb represents 1,4-bis(diphenylphosphino)butane, (o-anisyl)3P represents tri(2-methoxyphenyl)phosphine, Ph2P(t-Bu) represents tert-butyldiphenylphosphine, Ph2PCy represents diphenylcyclohexylphosphine, Cy3P represents tricyclohexylphosphine, dppf represents bisdiphenylphosphinoferrocene, dippf represents 1,1'-bis(diisopropylphosphino)ferrocene, Ad2nBuP represents n-butyldiadamantane phosphine, dtbpf represents 1,1'-bis(di-tert-butylphosphino)ferrocene, XantsPhos represents 4,5-bis(diphenylphosphino)-9,9'-dimethylxanthene, DPPA represents diphenylphosphoryl azide, NaN3 represents sodium azide, TMSN3 represents trimethylsilane azido, [Ir(OMe)(cod)]2 represents methoxy(cyclooctadiene)iridium dimer, and TmPhen represents 3,4,7,8-tetramethylphenanthroline. Pd(OAc)2 represents palladium acetate, Pd(MeCN)2Cl2 represents bisacetonitrile palladium(II) chloride, [PdCl(C3H5)]2 represents allylpalladium chloride dimer, Pd(TFA)2 represents palladium trifluoroacetate, and [(cinnamyl)PdCl]2 represents palladium(II) chloride dimer.

[0298] Compounds are named according to the conventional nomenclature in the art or using Software naming, commercially available compounds use supplier catalog names. DETAILED DESCRIPTION

[0299] The present application is described in detail below by way of examples, but this does not necessarily mean that there are any adverse limitations on the present application. The present application has been described in detail herein, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.

[0300] Unless otherwise specified, the raw materials used in the present invention are commercially available.

[0301] Example 1

[0302] Step 1

[0303] Compound 1 (1.0 kg, 3.49 mol) was dissolved in dichloromethane (10 L), cooled to -30°C, and triethylamine (1.17 kg, 11.53 mol) was added. Stirring to dissolve, methylsulfonyl chloride (560.1 g, 4.89 mol) was slowly added dropwise (addition completed over approximately 30 minutes). The reaction was incubated for 30 minutes, and a sample was taken for HPLC monitoring. The reaction was complete. The reaction solution was added dropwise to 5% aqueous citric acid (5 L) to quench the solution, ensuring that the aqueous phase was acidic (the product is unstable under alkaline conditions). The quenching temperature was maintained at 0-5°C. The addition was complete and stirred for 20 minutes. The organic phase was separated, washed with saturated brine (10 L), dried over anhydrous sodium sulfate, and distilled under reduced pressure (30°C) to obtain a pale yellow solid, Compound 2 (937.0 g, yield 100%, theoretical yield), which was used directly in the next step. 1 H NMR (400MHz, Chloroform-d) δ7.25-7.08 (m, 2H), 4.73 (dd, J=6.8, 1.3Hz, 1H), 2.13 (dddd, J=8.9, 5.8, 3.3, 1.3Hz, 1H) , 1.85 (ddd, J=7.5, 5.8, 4.3Hz, 1H), 1.49 (s, 9H), 1.35 (ddd, J=8.8, 7.5, 5.4Hz, 1H), 0.95 (ddd, J=5.4, 4.3, 3.3Hz, 1H).

[0304] Step 2

[0305] The hydrochloride of compound 3 (1.21 kg, 4.19 mol) was dispersed in DMF (4 L), triethylamine (706.9 g, 6.99 mol) was added and stirred to dissolve. At room temperature, a solution of compound 2 (937.0 g, 3.49 mol) in DMF (6 L) was added dropwise. The mixture was stirred at room temperature for 20 minutes, and a sample was taken for HPLC monitoring to confirm that the reaction was complete. Cuprous iodide (66.52 g, 349.6 mmol) and 1,10-phenanthroline (125.9 g, 698.5 mmol) were added to the reaction solution, stirred to dissolve, and iodobenzene acetate (1.24 kg, 3.84 mol) was added and stirred at room temperature for 40 minutes. Sampling was monitored by HPLC. When the reaction was complete, 10% aqueous sodium sulfite solution (10 L) was added to the reaction solution to quench it. The reaction solution was extracted with ethyl acetate (10 L × 2). The combined organic phases were washed sequentially with 10% aqueous EDTA disodium salt solution (5 L × 2), 5% aqueous citric acid solution (5 L), and water (5 L). The solvent was removed by distillation under reduced pressure. The crude product was slurried with methyl tert-butyl ether (5 L) and n-heptane (7 L) to obtain brown solid compound 4 (1.08 kg, yield 65%). 1 H NMR (400MHz, DMSO-d6) δ12.17 (s, 1H), 10.24 (s, 1H), 8.35 (dd, J=10.2, 8.4Hz, 1H), 7.82 (dd, J=8.4, 1.9Hz, 1H), 7.10 (s, 1H), 5.02 (s, 1H), 2.12-2.02 (m, 1H), 1.98 (ddd, J=7.5, 5.9, 4.3Hz, 1H), 1.49 (s, 9H), 1.31 (s, 9H), 1.26-1.14 (m, 1H), 0.90 (d, J=3.7Hz, 1H).

[0306] Step 3

[0307] Compound 4 (1.08 kg, 2.28 mol) was dissolved in DCM (10.8 L). Pyridine (541.2 g, 6.84 mol) and benzaldehyde (290.5 g, 2.74 mol) were added and stirred to dissolve. SelectFluor (1.6 kg, 4.56 mol, pre-micronized) was added. The reaction was stirred at room temperature for 16-24 hours (the specific reaction was stopped when the ratio of Compound 4 to Compound 5 was approximately 1:1, depending on the HPLC results). A 10% aqueous sodium bisulfite solution (5.4 L) was added and stirred for 1 hour. The organic phase was separated and washed twice. The organic phase was washed sequentially with 10% aqueous citric acid solution (5 L x 2) and saturated brine (5.4 L). The organic phases were combined and the solvent was removed by pressure distillation. The crude product was purified by column chromatography (10 kg, 100-200 mesh silica gel, DCM / heptane = 1:1 to 3:1) to obtain the crude product. The crude product was slurried in methanol (500 mL) to obtain a white solid. The solid was dissolved in tetrahydrofuran (2 L) and added dropwise to n-heptane (10 L). The solid precipitated and was dried to obtain white solid compound 5 (470 g, yield 41%). 1 H NMR (400MHz, DMSO-d6) δ12.50 (s, 1H), 10.28 (s, 1H), 8.26 (dd, J=10.2, 8.4Hz, 1H), 7.82 (dd, J=8.5, 1.8Hz, 1H), 5.12 (d, J=1.2Hz, 1H) , 2.16-2.05 (m, 1H), 1.99 (ddd, J=7.6, 5.9, 4.1Hz, 1H), 1.48 (s, 9H), 1.30 (s, 9H), 1.22 (td, J=7.6, 4.7Hz, 1H), 0.97 (q, J=4.3Hz, 1H).

[0308] Step 4

[0309] Dissolve diisopropylamine (1.16 kg, 11.48 mol) in anhydrous tetrahydrofuran (4.7 L), cool to -30 to -40°C, and add n-butyl lithium (4.6 L, 11.48 mol, 2.5 M) dropwise to prepare an LDA solution for later use;

[0310] Isopropyl acetoacetate (827.2 g, 5.74 mol) was dissolved in anhydrous tetrahydrofuran (4.7 L), referred to as S1 solution;

[0311] Compound 5 (470 g, 0.956 mol) was dissolved in anhydrous tetrahydrofuran (9.4 L), referred to as S2 solution;

[0312] The PFR equipment was built, and the material flow rates were calculated as follows: LDA solution = 0.96 mL / min, S2 = 0.5 mL / min, S3 = 0.88 mL / min;

[0313] Run the PFR equipment at an external temperature of -25 to -35°C, pump S1 and LDA into the reaction pipeline, react for 10 minutes, and complete reaction of acetoacetic acid isopropyl anion; pump S2 into the pipeline, react for 10 minutes, monitor by HPLC, and complete reaction, and pump in saturated NH4Cl solution (flow rate: 3.5 mL / min).

[0314] The reaction solution was collected, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (10 L), the organic phases were combined, washed with 5% citric acid aqueous solution (5 L), washed with saturated brine (5 L), dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a crude product;

[0315] The crude product was dissolved in methyl tert-butyl ether (1 L), and n-heptane (10 L) was added. The mixture was stirred and beaten overnight to precipitate a solid. The solid was filtered and the filter cake was dried to obtain a yellow solid compound 6 (610 g, yield 40.7%). MS (ESI) m / z (M+H) + =636.2.

[0316] Step 5

[0317] Compound 6 (1.0 kg, 1.57 mol) was weighed and dissolved in dichloromethane (10 L). The reaction solution was cooled to 5-10°C and nitrogen was bubbled through the reaction solution. 2,6-Lutidine (0.51 kg, 4.72 mol) was added dropwise, followed by trimethylsilyl trifluoromethanesulfonate (1.05 kg, 4.72 mol). The mixture was slowly warmed to room temperature with stirring. The reaction was allowed to react for 2 hours, and samples were taken for HPLC monitoring. Upon completion of the reaction, the nitrogen bubbler was removed, the reaction solution was cooled to 0-10°C, and 5% aqueous lithium hydroxide solution was added dropwise until the pH reached 12. The reaction solution was stirred at room temperature for 4 hours. Sampling was monitored by HPLC. The reaction was complete and the insoluble matter was removed by filtration. The organic phase was separated and activated carbon (100 g) was added to the aqueous phase. The mixture was stirred at room temperature for 4 hours and filtered. The filter residue was washed with a 5% aqueous lithium hydroxide solution. The aqueous phases were combined and the pH was adjusted to 5 with 2M dilute hydrochloric acid. The solid was precipitated and filtered. The filter cake was washed with water and dried to obtain a light yellow solid compound 7 (190 g, yield 33.7%). 1 H NMR (400MHz, DMSO-d6) δ11.88 (s, 1H), 10.48 (s, 1H), 7.86 (dd, J=10.4, 8.4Hz, 1H), 6.73 (s, 2H), 6.39 (dd, J=8.4, 2.4Hz, 1H), 5.93 (d, J=2 .0Hz, 1H), 5.44 (s, 1H), 5.36 (d, J=2.0Hz, 1H), 2.81-2.69 (m, 1H), 2.29-2.17 (m, 1H), 1.30 (td, J=8.0, 4.8Hz, 1H), 0.53 (q, J=4.4Hz, 1H).

[0318] Step 6

[0319] Compound 7 (190 g, 0.53 mol) was dissolved in tetrahydrofuran (1.6 L), and triethylamine (80.3 g, 0.80 mol) was added. The reaction solution was cooled to 0-5°C, and a solution of p-toluenesulfonyl chloride (110.78 g, 0.58 mol) in tetrahydrofuran (400 mL) was added dropwise. The mixture was stirred for 2 hours at this temperature and sampled for HPLC monitoring. When the reaction was complete, ethyl acetate (1 L × 2) was added for extraction. The organic phases were combined, washed with water (1 L) and saturated brine (1 L) in sequence, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. Isopropanol (2 L) was added, and the mixture was heated to reflux for 2 hours. The mixture was cooled to room temperature to precipitate a solid, which was filtered. The filter cake was washed with isopropanol and dried to obtain a gray solid compound 7a (230 g, yield 84.6%). 1 H NMR (400MHz, DMSO-d6) δ11.94 (s, 1H), 7.90-7.78 (m, 3H), 7.50 (d, J=8.0Hz, 2H), 6.73 (s, 2H), 6.39 (dd, J=8.4, 2.4Hz, 1H), 6.25 (d, J=2.4Hz, 1H), 5.71 ( d, J=2.4Hz, 1H), 5.49 (s, 1H), 2.88-2.79 (m, 1H), 2.43 (s, 3H), 2.30-2.20 (m , 1H), 1.34 (td, J=8.0, 4.8Hz, 1H), 0.67 (q, J=4.4Hz, 1H).MS (ESI) m / z (M+H) + =512.12,

[0320] Step 7

[0321] Compound 7a (217.5 g, 425.2 mmol) and anhydrous potassium acetate (125.1 g, 1275 mmol) were dispersed in tert-amyl alcohol (2.6 L). Nitrogen was bubbled through the reaction solution. After 1 hour, BisB(pin) (161.9 g, 637.8 mmol), diphenyl tert-butyl phosphine (5.15 g, 21.2 mmol), and allyl palladium chloride dimer (1.87 g, 5.10 mmol) were added in sequence. The nitrogen bubbler was removed and a nitrogen balloon was installed, replacing the nitrogen balloon twice. The mixture was heated to 70°C and reacted for 16 hours. Sampling and analysis showed that the reaction was complete. The reaction solution was cooled to room temperature, diluted with ethyl acetate (2 L), filtered, and the filtrate was distilled under reduced pressure to remove the solvent. Methyl tert-butyl ether (2 L) and 5% lithium hydroxide aqueous solution (2 L) were added to the remaining solid, stirred at room temperature for 2 hours, filtered to remove insoluble matter, the filter cake was washed with 5% lithium hydroxide aqueous solution, the filtrate was combined, and the layers were allowed to stand. The aqueous phase was washed with methyl tert-butyl ether (1 L), and the aqueous phase was adjusted to a solution pH of 4-5 with 2M dilute hydrochloric acid. The precipitated solid was filtered, the filter cake was washed with water, and dried with air at 55°C to give a gray solid compound 8 (163.7 g, yield 87%, purity 95%). 1 H NMR (400MHz, DMSO-d6) δ11.92 (s, 1H), 8.32 (s, 2H), 7.86 (dd, J=10.4, 8.4Hz, 1H), 6.73 (s, 2H), 6.52 (d, J=6.8Hz, 2H), 6.39 (dd, J=8.4 , 2.0Hz, 1H), 5.53 (s, 1H), 2.89-2.76 (m, 1H), 2.29-2.18 (m, 1H), 1.32 (td, J=8.0, 4.8Hz, 1H), 0.53 (q, J=4.4Hz, 1H).MS (ESI) m / z (M+H) + =386.12

[0322] The Pd source, Pd dosage, ligand, and reaction temperature in step 7 above were screened, and the results are summarized as follows:

[0323] Preparation of compound 8

[0324] Step 8

[0325] Compound 8 (163.7 g, 425.2 mmol), compound (I-9) (115.8 g, 446.4 mmol), and potassium bicarbonate (127.6 g, 1275.6 mmol) were dissolved in tetrahydrofuran (2.5 L) and water (500 mL). Nitrogen was bubbled into the reaction solution. After 1 hour, bisacetonitrile palladium dichloride (2.21 g, 8.58 mmol) and DPEphos (4.62 g, 8.58 mmol) were added in sequence. The nitrogen bubbler was removed and replaced with a nitrogen balloon, which was replaced twice. The mixture was heated to 60°C and reacted for 16 hours. Sampling and analysis indicated that the reaction was complete. The reaction solution was cooled to room temperature, and water (1 L) and ethyl acetate (1 L) were added. The mixture was stirred for 10 minutes, and the insoluble matter was removed by filtration. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (1 L x 2). The organic phases were combined, and activated carbon (32 g) was added. The mixture was stirred at room temperature for 2 hours. The activated carbon was removed by filtration, and the filtrate was added with mercapto silica gel (32 g, 100 mesh) and stirred at room temperature for 2 hours. The mixture was filtered, and the residue was washed with tetrahydrofuran. The filtrates were combined, and the solvent was removed by distillation under reduced pressure. Compound 36 (202.3 g, 90% yield, 97% purity) was obtained by column chromatography. 1 H NMR (400MHz, DMSO-d6) δ11.88 (d, J=1.8Hz, 1H), 9.55 (s, 1H), 7.80 (dd, J=10.5, 8.3Hz, 1H), 7.75-7.66 (m, 3H), 6.69 (s, 2H), 6.33 (dd, J=8.4, 2.1Hz, 1H), 5.89 ( s, 2H), 5.45 (d, J=1.3Hz, 1H), 2.65 (dtd, J=8.2, 4.2, 3.7, 2.0Hz, 1H), 2.21-2.0 8(m, 1H), 1.26 (td, J=8.0, 4.8Hz, 1H), 0.46 (q, J=4.3Hz, 1H).MS(ESI)m / z: (M+H) + =520.1.

[0326] The Pd source, Pd dosage, ligand, and base in step 8 above were screened, and the results are summarized as follows:

[0327] Preparation of compound 36

[0328] Example 2:

[0329] Compound 7a (51.1 g, 100 mmol) was dissolved in tetrahydrofuran (500 mL) and water (250 mL). The atmosphere was replaced with nitrogen three times. Potassium bicarbonate (35.0 g, 350 mmol), I-11 (38.1 g, 105 mmol), Pd(OAc)2 (0.27 g, 1.2 mmol), and dppb (0.51 g, 1.2 mmol) were added sequentially under nitrogen protection. The mixture was heated to 50°C and reacted for 16 hours. Samples were taken for HPLC monitoring and the reaction was complete. The reaction solution was cooled to room temperature, and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (250 mL x 2). The organic phases were combined and washed sequentially with 5% aqueous citric acid, water, and saturated brine. The crude product was concentrated and purified by column chromatography to obtain compound 36 (41.5 g, 80% yield).

[0330] The Pd source, Pd dosage, ligand, base, solvent and temperature in Example 2 above were screened, and the results are summarized as follows:

[0331] Preparation of compound 36

[0332] Example 3:

[0333] Step 1:

[0334] Compound 1-B (7.0 g, 25.5 mmol) was dissolved in dichloromethane (70 mL), and the atmosphere in the reaction flask was replaced with N2. The reaction solution was cooled to -30°C, and triethylamine (8.5 g, 84.1 mmol) was added. Methanesulfonyl chloride (4.1 g, 35.7 mmol) was slowly added dropwise. The reaction was incubated for 60 minutes, and samples were taken for HPLC monitoring. The reaction solution was quenched by adding dropwise to 5% aqueous citric acid solution (100 mL), maintaining the quenching temperature at 0-5°C, and stirred for 20 minutes. The organic phase was separated, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure (30°C). The mixture was then purified by column chromatography (100-200 mesh silica gel, EA / heptane = 1:2 to 1:1) to obtain compound 2-B (5.2 g, yield 80%) as a pale yellow solid. 1 H NMR (400MHz, Chloroform-d) δ7.34-7.22 (m, 1H), 7.12 (d, J=13.2Hz, 1H), 5.01-4.85 (m, 1H), 2.7 5-2.55(m, 2H), 2.52-2.39(m, 1H), 2.07-1.96(m, 1H), 1.56(s, 9H).MW=256.26, MS(ESI)m / z(M+H) + =257.09.

[0335] Step 2:

[0336] Compound 3 was dispersed in DMF (25 mL), triethylamine (4.1 g, 41.0 mmol) was added, and the mixture was stirred to dissolve. A solution of compound 2-B (5.2 g, 20.5 mmol) in DMF (25 mL) was added dropwise at room temperature. The mixture was stirred at room temperature for 30 minutes, and a sample was taken for HPLC monitoring to confirm the reaction was complete. Cuprous iodide (0.38 g, 2.0 mmol) and 1,10-phenanthroline (0.74 g, 4.1 mmol) were added to the reaction solution, and the mixture was stirred to dissolve. Iodobenzene acetate (7.2 g, 22.5 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Sampling was monitored by HPLC. After the reaction was complete, 10% aqueous sodium sulfite solution (40 mL) was added to the reaction solution to quench the reaction. The reaction solution was extracted with ethyl acetate (200 mL×2). The combined organic phases were washed sequentially with 10% aqueous EDTA disodium salt solution (20 mL×2), 5% aqueous citric acid solution (20 mL), and water (20 mL). The solvent was distilled off under reduced pressure, and the mixture was purified by column chromatography (100-200 mesh silica gel, DCM / MeOH=50:1 to 30:1) to give compound 4-B (6.6 g, 70% yield) as a brown solid. 1 H NMR (400MHz, Chloroform-d) δ9.78 (s, 1H), 8.54 (t, J = 8.8Hz, 1H), 7.90 (d, J = 8.4Hz, 1H), 7.28 (s, 1H), 6.99 (s, 1H), 5 .29 (d, J=8.0Hz, 1H), 2.99-2.70 (m, 1H), 2.56-2.18 (m, 3H), 1.51 (s, 9H), 1.43 (s, 9H).MW=461.49, MS (ESI) m / z (M+H) + =462.18

[0337] Step 3:

[0338] Compound 4-B (6.6 g, 14.4 mmol) was dissolved in DCM (52 mL). Pyridine (3.4 g, 43.2 mmol) and benzaldehyde (1.8 g, 17.3 mmol) were added and stirred to dissolve. Selectfluor (10.2 g, 28.8 mmol) was added. The mixture was stirred at room temperature for 24-36 hours. A 10% aqueous sodium bisulfite solution (25 mL) was added and stirred for 1 hour. The organic phase was separated and washed twice. The organic phase was washed sequentially with a 10% aqueous citric acid solution (20 mL x 2) and saturated brine (20 mL). The organic phases were combined and the solvent was removed by pressure distillation. The target compound was purified by column chromatography (100-200 mesh silica gel, EA / heptane = 1:2 to 1:1) to obtain 5-B (3.4 g, 50% yield) as a brown solid. 1H NMR (400MHz, Chloroform-d) δ10.48 (s, 1H), 8.42 (t, J=9.2Hz, 1H), 7.90 (d, J=7.6Hz, 1H), 7.20 (s, 1H), 5.32 (d, J=7.6Hz , 1H), 2.89-2.74(m, 1H), 2.66-2.51(m, 2H), 2.47-2.32(m, 1H), 1.52(s, 9H), 1.49(s, 9H).MW=479.48, MS(ESI)m / z(M+H) + =480.19.

[0339] Step 4:

[0340] Dissolve diisopropylamine (35.9 g, 355.2 mmol) in anhydrous tetrahydrofuran (110 mL), cool to -30-40°C, and add n-butyllithium (222 mL, 355.2 mmol, 1.6 M) dropwise to prepare an LDA solution. Dissolve isopropyl acetoacetate (25.9 g, 177.6 mmol) in anhydrous tetrahydrofuran (110 mL) and add this solution dropwise to the prepared LDA solution. Stir at -30°C for 30 min. Dissolve compound 5-B (14.2 g, 29.6 mmol) in anhydrous tetrahydrofuran (220 mL) and add this solution dropwise to the reaction mixture. Stir at -30°C for 30 min. The reaction was complete, and a saturated NH4Cl solution was added by pumping. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (200 mL). The organic phases were combined and washed sequentially with 5% citric acid aqueous solution (100 mL) and saturated brine (100 mL), dried over anhydrous sodium sulfate, and distilled under reduced pressure to obtain a crude product. The crude product was dissolved in methyl tert-butyl ether (20 mL). The methyl tert-butyl ether solution of the crude product was added dropwise to n-heptane (200 mL), stirred and slurried, and a solid precipitated. The solid was filtered and the filter cake was dried to obtain a yellow solid 6-B (14.8 g, yield 80%). MW = 623.65, MS (ESI) m / z (M+H) + =624.30.

[0341] Step 5:

[0342] Compound 6-B (14.8 g, 23.5 mmol) was weighed and dissolved in dichloromethane (150 mL). 2,6-Lutidine (15.1 g, 141 mmol) and TMSOTf (29.1 g, 141 mmol) were added and stirred at room temperature until the reaction was complete. The reaction solution was cooled to 0-10°C and 5% aqueous sodium hydroxide solution was added dropwise until the pH of the reaction solution reached 12. The solution was stirred at room temperature for 2 hours. After the reaction was complete, the insoluble matter was removed by filtration. The organic phase was separated and dilute hydrochloric acid solution was added to the aqueous phase to adjust the pH of the aqueous phase to approximately 6-7. Solids precipitated. The solution was filtered and dried to obtain compound 7-B (7.7 g, yield 95%). 1 H NMR (400MHz, DMSO-d6) δ11.67 (s, 1H), 10.60 (s, 1H), 7.88 (dd, J=10.4, 8.0Hz, 1H), 6.76 (s, 2H), 6.39 (dd, J=8.4, 2.4Hz, 1H), 5 .87 (s, 1H), 5.63 (d, J=8.4Hz, 1H), 5.47 (d, J=2.0Hz, 1H), 3.14-2.97 (m, 2H), 2.49-2.24 (m, 2H).MW=345.31, MS (ESI) m / z (M+H) + =346.03.

[0343] Step 6:

[0344] Weigh compound 7-B (7.7 g, 22.3 mmol) and dissolve it in tetrahydrofuran (80 mL). Add triethylamine (3.4 g, 33.4 mmol), place the reaction in an ice bath, and add a tetrahydrofuran solution of p-toluenesulfonyl chloride (5.3 g, 27.2 mmol) dropwise. After the addition, stir the reaction at room temperature overnight. After the reaction is complete, add water and ethyl acetate, separate the organic phase, extract the aqueous phase with ethyl acetate (200 mL), combine the organic phases, wash with water (100 mL), wash with saturated brine (100 mL), dry over anhydrous sodium sulfate, and column chromatography (100-200 mesh silica gel, EA / heptane = 2:3 to 1:1) to obtain a brown solid product 7a-B (10.2 g, yield 90%). 1H NMR (400MHz, DMSO-d6) δ11.74 (s, 1H), 7.90-7.81 (m, 3H), 7.51 (d, J=8.4Hz, 2H), 6.76 (s, 2H), 6.39 (dd, J=8.4, 2.4Hz, 1H), 6.22-6.16 (m, 1H), 5.78 (d, J=2.4Hz, 1H), 5.65 (dd, J=8.8, 2.4Hz, 1H), 3.25-3.02 (m, 2H), 2.56-2.50 (m, 1H), 2.43 (s, 3H), 2.26-2.16 (m, 1H).MW=499.49, MS (ESI) m / z (M+H) + =500.05.

[0345] Step 7:

[0346] Compound 7a-B (3.4 g, 6.8 mmol) and anhydrous potassium acetate (2.0 g, 20.4 mmol) were dispersed in tert-amyl alcohol (35 mL). BisB(pin) (2.6 g, 10.2 mmol), diphenyl tert-butyl phosphine (0.080 g, 0.34 mmol), and allylpalladium chloride dimer (0.030 g, 0.082 mmol) were added sequentially. The atmosphere was purged with nitrogen three times. The mixture was heated to 70°C and allowed to react for 16 hours. Samples were taken for analysis and the reaction was complete, and the reaction solution was concentrated. Dichloromethane (100 mL) and 10% aqueous lithium hydroxide solution (35 mL) were added to the concentrated solution. The mixture was stirred at room temperature for 1 hour. Insoluble matter was removed by filtration, and the filter cake was washed with water. The filtrates were combined, allowed to stand for separation, and the aqueous phase was washed with dichloromethane (50 mL). The mixture was allowed to stand and the layers were separated. The aqueous phase was adjusted to pH 5-6 with 2M dilute hydrochloric acid to precipitate a solid which was filtered. The filter cake was washed with water and dried under air at 55°C to give a light yellow solid: 8-B (2.0 g, yield 80%). 1 H NMR (400MHz, DMSO-d6) δ11.74 (s, 1H), 8.46 (s, 2H), 7.86 (dd, J=10.4, 8.4Hz, 1H), 6.73 (s, 2H), 6.62 (s, 1H), 6.45 (s, 1H), 6.39 (dd, J= 8.4, 2.0Hz, 1H), 5.71 (dd, J=8.8, 1.6Hz, 1H), 3.26-3.03 (m, 2H), 2.49-2.40 (m, 1H), 2.35-2.21 (m, 1H).MW=373.13, MS (ESI) m / z (M+H) + =374.04.

[0347] Step 8:

[0348] Compound 8-B (0.50 g, 1.34 mmol) and compound I-9 (0.36 g, 1.41 mmol) were dissolved in tetrahydrofuran (10 mL) and water (2 mL). The atmosphere was purged with nitrogen three times, and then bisacetonitrile palladium dichloride (0.007 g, 0.027 mmol) and DPEphos (0.014 g, 0.027 mmol) were added sequentially. The atmosphere was purged with nitrogen three times. The mixture was heated to 60°C and allowed to react for 16 hours. Samples were taken for analysis and the reaction was complete. The reaction solution was cooled to room temperature, and water (50 mL) and ethyl acetate (50 mL) were added. The mixture was stirred for 10 minutes and filtered to remove insoluble matter. The layers were allowed to stand and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (40 mL x 2). The organic phases were combined, and mercapto silica gel (1.5 g, 100 mesh) was added. The mixture was stirred at room temperature for 2 hours. The residue was filtered and washed with ethyl acetate. The filtrates were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was removed by distillation under reduced pressure. The product was purified by column chromatography (100-200 mesh silica gel, DCM / MeOH = 30:1) to give a light yellow solid compound 36-B (0.54 g, yield 80%). 1 H NMR (400MHz, DMSO-d6) δ11.72 (s, 1H), 9.66 (s, 1H), 7.88 (dd, J=10.8, 8.0Hz, 1H), 7.83-7.77 (m, 2H), 7.76 (t, J=1.6Hz, 1H), 6.76 (s, 2H), 6.40 (dd, J=8.4, 2.4Hz, 1H), 6.02 (s, 1H), 5.94 (s, 1H), 5.71 (dd, J=8.8, 2.0Hz, 1H), 3.15-2.9 4(m, 2H), 2.49-2.42(m, 1H), 2.32-2.20(m, 1H).MW=507.89MS, (ESI)m / z(M+H) + =508.08.

[0349] Example 4

[0350] Compound 7a-B (0.50 g, 1 mmol) was dissolved in tetrahydrofuran (5 mL) and water (2.5 mL). The atmosphere was replaced with nitrogen three times. Potassium bicarbonate (0.35 g, 3.50 mmol), compound I-11 (0.38 g, 1.05 mmol), Pd(OAc)2 (0.003 g, 0.012 mmol), and dppb (0.005 g, 0.012 mmol) were added sequentially under nitrogen. The mixture was heated to 50°C and reacted for 16 hours. Samples were taken for HPLC monitoring, indicating the reaction was complete. The reaction solution was cooled to room temperature, and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (15 mL x 2). The combined organic phases were washed sequentially with 5% aqueous citric acid, water, and saturated brine, and concentrated. The crude product was purified by column chromatography to obtain compound 36-B (0.39 g, 76% yield).

[0351] Example 5

[0352] Step 1A:

[0353] To a 250 mL three-necked flask, raw materials III-1 (7.5 g, 36.3 mmol), III-2 (18.4 g, 50.2 mmol), potassium acetate (11.4 g, 116.2 mmol), and 75 mL of dioxane were added. The mixture was vacuum-substituted 5 times, and PdCl2 (dppf) (2.6 g, 3.6 mmol) was added under nitrogen protection. The mixture was heated to 80-85°C with stirring and reacted for 19 hours. After sampling and detection, the reaction was cooled to 20-30°C, filtered, and the filtrate was concentrated under reduced pressure at 55-60°C until there was no fraction. After adding 75 mL of n-heptane and stirring, the mixture was filtered and concentrated to give an oily substance III-3 (19.5 g, purity 70%-75%), MW = 309.64, MS (ESI) m / z (M+H) + =310.30, which was used directly in the next reaction.

[0354] 1 H NMR (400MHz, DMSO-d6) δ7.27 (d, J=2.4Hz, 1H), 7.14 (dd, J=8.8, 2.4Hz, 1H), 6.6 2 (d, J=10.8Hz, 1H), 5.62 (s, 2H), 1.41 (q, J=7.6Hz, 8H), 0.89 (t, J=7.6Hz, 12H).

[0355] Step 1B: (Another preparation method of compound III-3)

[0356] Weigh compound III-4 (0.51 g, 4 mmol), add cyclopentyl methyl ether (3 mL), and stir at room temperature to dissolve for use.

[0357] Weigh [Ir(OMe)(cod)]2 (0.024 g, 0.006 mmol) and add cyclopentyl methyl ether (0.5 mL). Weigh Tmphen (0.028 g, 0.024 mmol) and add cyclopentyl methyl ether (0.5 mL). Combine the [Ir(OMe)(cod)]2 solution in cyclopentyl methyl ether and the Tmphen solution in cyclopentyl methyl ether and stir at room temperature for 10 min.

[0358] Weigh compound III-2 (2.2 g, 6 mmol), add cyclopentyl methyl ether (5.6 mL), and stir at room temperature. Add a mixed solution of [Ir(OMe)(cod)]2 and Tmphen in cyclopentyl methyl ether, stir at room temperature for 10 minutes, and add a solution of compound HI-4 in cyclopentyl methyl ether. Rinse the reaction flask with cyclopentyl methyl ether (1.0 mL). Stir the reaction at room temperature for 10 minutes, raise the temperature to 80°C-90°C, and stir. After the reaction is complete, concentrate the reaction solution and purify it by column chromatography to obtain compound III-3 (1.3 g, 90% yield).

[0359] Step 2A:

[0360] Acetic anhydride (20 g, 195.9 mmol) and formic acid (10.8 g, 234.6 mmol) were heated to 55-60°C and reacted for two hours to prepare formic acid and acetic anhydride, which was sealed for later use.

[0361] To compound III-3 (6.5 g, 12.1 mmol), add 30 mL of toluene, stir and dissolve, and cool to 0-10°C. Weigh 2.7 g of the prepared formic acid acetic anhydride and 15 mL of toluene, stir and dissolve, and slowly add dropwise to the above reaction solution, controlling the addition temperature at 0-10°C. After the addition is complete, stir for 30 minutes, and concentrate the reaction solution under reduced pressure at 55-60°C until there is no fraction. Add 15 mL of pyridine and DPPA (4.6 g, 16.7 mmol), stir and heat to 90-95°C, and react for 30-35 hours. Sample HPLC monitoring, the reaction is complete, the reaction solution is concentrated, and purified by column chromatography (100-200 mesh silica gel, heptane: EA = 10: 1) to obtain compound I-11 (3.7 g, yield 85%). MW = 362.66, MS (ESI) m / z (M+H) + =363.20.

[0362] 1H NMR (400MHz, DMSO-d6) δ9.78 (d, J=2.4Hz, 1H), 7.86 (dd, J=8.4, 2.4Hz, 1H), 7.81 (d , J=2.4Hz, 1H), 7.70 (d, J=8.8Hz, 1H), 1.56 (q, J=8.0Hz, 8H), 0.76 (t, J=8.0Hz, 12H)

[0363] Step 2B (Another Preparation Method for Compound I-11)

[0364] Compound III-3 (6.5 g, 12.1 mmol), triethyl orthoformate (5.4 g, 36.3 mmol), and glacial acetic acid (130 mL) were added to a reaction flask. The atmosphere in the flask was replaced with argon three times, and NaN3 (2.3 g, 36.3 mmol) (an azide reagent such as TMS-N3) was added. The reaction was stirred at room temperature (20°C) for 4 hours. Samples were taken for HPLC monitoring, and the reaction was complete. Saturated aqueous Na2CO3 solution was added to adjust the pH to approximately 8. The aqueous phase was extracted twice with EA. The organic phases were combined and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed by distillation under reduced pressure. The mixture was purified by column chromatography (100-200 mesh silica gel, heptane:EA = 10:1) to obtain compound I-11 (3.7 g, 85% yield).

[0365] In the description of this specification, the reference terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" mean that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0366] Although the embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A method for preparing a compound represented by formula (I-10) or an optical isomer thereof, characterized in that: The compound represented by formula (I-8) is contacted with the compound represented by formula (I-9) to obtain the compound represented by formula (I-10) or an optical isomer thereof, Wherein, R5 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R6 is independently selected from F, Cl and Br.

2. A compound represented by formula (I-8) or an optical isomer thereof, in, R5 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R6 is independently selected from F, Cl and Br.

3. A compound represented by formula (I-7) or formula (I-7a) or an optical isomer thereof, in, R5 is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R6 is independently selected from F, Cl and Br.

4. A compound represented by formula (I-6) or an optical isomer thereof, in, R2, R4, and R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; R3 are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; R6 are each independently selected from F, Cl and Br.

5. A compound represented by formula (I-5) or an optical isomer thereof, in, R2, R4, and R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; R6 are each independently selected from F, Cl and Br.

6. A compound represented by formula (I-4) or an optical isomer thereof, in, R2, R4, and R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl.

7. A compound represented by formula (I-2) or an optical isomer thereof, in, R1 are independently selected from H, Cl and Br; R2 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl.

8. A compound represented by formula (I-1) or an optical isomer thereof, in, R1 are independently selected from H, Cl and Br; R2 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl.

9. A method for preparing a compound represented by formula (I-10) or an optical isomer thereof, characterized in that: include: Using one or more compounds represented by formula (I-8), formula (I-7), formula (I-7a), formula (I-6), formula (I-5), formula (I-4), formula (I-2), or formula (I-1) as intermediates, wherein R1 is independently selected from H, Cl and Br; R2, R4, and R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; R3 are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; R6 are each independently selected from F, Cl and Br.

10. The compound or optical isomer thereof according to claim 2, characterized in that The compound represented by formula (I-8) is prepared by the following method, comprising: subjecting the compound represented by formula (I-7a) to a borylation reaction.

11. The compound or optical isomer thereof according to claim 3, characterized in that The compound represented by formula (I-7a) is prepared by the following method, comprising: subjecting the compound represented by formula (I-7) to a sulfonylation reaction.

12. The compound or optical isomer thereof according to claim 3, characterized in that The compound represented by formula (I-7) is prepared by the following method, comprising: subjecting the compound represented by formula (I-6) to a ring-closure reaction.

13. The compound according to claim 4 or its optical isomer, characterized in that The compound represented by formula (I-6) is prepared by the following method, comprising: subjecting the compound represented by formula (I-5) to a ring-opening reaction.

14. The compound or optical isomer thereof according to claim 5, characterized in that The compound represented by formula (I-5) is prepared by the following method, comprising: subjecting the compound represented by formula (I-4) to a halogenation reaction.

15. The compound or optical isomer thereof according to claim 6, characterized in that The compound represented by formula (I-4) is prepared by the following method, comprising: subjecting the compound represented by formula (I-2) to a ring-closure reaction.

16. The compound according to claim 7 or its optical isomer, characterized in that The compound represented by formula (I-2) is prepared by the following method, comprising: subjecting the compound represented by formula (I-1) to a dehydration reaction.

17. Use of a compound of formula (I-8) according to claim 2 or 9 or an optical isomer thereof, or a compound of formula (I-7) according to claim 3 or 12 or an optical isomer thereof, or a compound of formula (I-7a) according to claim 3 or 11 or an optical isomer thereof, or a compound of formula (I-6) according to claim 4 or 13 or an optical isomer thereof, or a compound of formula (I-5) according to claim 5 or 14 or an optical isomer thereof, or a compound of formula (I-4) according to claim 6 or 15 or an optical isomer thereof, or a compound of formula (I-2) according to claim 7 or 16 or an optical isomer thereof, or a compound of formula (I-1) according to claim 8 or an optical isomer thereof in preparing a compound of formula (I-10).

18. A method for preparing a compound represented by formula (I-10-a) or an optical isomer thereof, characterized in that: include: Obtaining a compound represented by formula (I-8-a) or a compound represented by formula (I-7-a) or a compound represented by formula (I-7a-a) or a compound represented by formula (I-6-a) or a compound represented by formula (I-5-a) or a compound represented by formula (I-4-a) or a compound represented by formula (I-2-a) or a compound represented by formula (I-1-a), wherein R1 is independently selected from H, Cl and Br; R2, R4, and R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl, and p-methoxybenzyl; R3 are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; R6 are each independently selected from F, Cl and Br.

19. A method for preparing a compound represented by formula (I-10) or an optical isomer thereof, characterized in that: The compound represented by formula (I-7a) is contacted with the compound represented by formula (I-11) to obtain the compound represented by formula (I-10) or an optical isomer thereof, in, R5 are each independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R6 are independently selected from Cl and Br.

20. A compound represented by formula (I-11) and formula (III-3) or an optical isomer thereof, 21. The compound according to claim 20 or its optical isomer, characterized in that The compound represented by formula (I-11) is prepared by the following method, comprising: subjecting the compound represented by formula (III-3) to tetrazole ring-closure reaction.

22. The compound according to claim 21 or its optical isomer, characterized in that The compound represented by formula (III-3) is prepared by the following method, comprising: reacting compound (III-1) or compound (III-4) with compound (III-2).

23. Use of the compound represented by formula (I-8-a) or its optical isomer, or the compound represented by formula (I-7-a) or its optical isomer, or the compound represented by formula (I-7a-a) or its optical isomer, or the compound represented by formula (I-6-a) or its optical isomer, or the compound represented by formula (I-5-a) or its optical isomer, or the compound represented by formula (I-4-a) or its optical isomer, or the compound represented by formula (I-2-a) or its optical isomer, or the compound represented by formula (I-1-a) or its optical isomer, or the compound represented by formula (III-3) in the preparation of the compound represented by formula (I-10-a).

24. A method for preparing a compound represented by formula (II-10) or an optical isomer thereof, characterized in that: The compound represented by formula (II-8) is contacted with the compound represented by formula (I-9) to obtain the compound represented by formula (II-10) or an optical isomer thereof, Among them, R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 6a F, Cl and Br are selected independently.

25. A compound represented by formula (II-8) or an optical isomer thereof, in, R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 6a are independently selected from F, Cl and Br.

26. A compound represented by formula (II-7) or formula (II-7a) or an optical isomer thereof, in, R 5a R is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; 6a are independently selected from F, Cl and Br.

27. A compound represented by formula (II-6) or an optical isomer thereof, in, R 2a 、R 4a 、R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R 3a are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; R 6a are independently selected from F, Cl and Br.

28. A compound represented by formula (II-5) or an optical isomer thereof, in, R 2a 、R 4a 、R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R 6a are independently selected from F, Cl and Br.

29. A compound represented by formula (II-4) or an optical isomer thereof, in, R 2a 、R 4a 、R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl.

30. A compound represented by formula (II-2) or an optical isomer thereof, in, R 1a are independently selected from H, Cl and Br; R 2a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl.

31. A compound represented by formula (II-1) or an optical isomer thereof, in, R 1a are independently selected from H, Cl and Br; R 2a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl.

32. A method for preparing a compound represented by formula (II-10) or an optical isomer thereof, characterized in that: include: Using one or more compounds represented by formula (II-8), formula (II-7), formula (II-7a), formula (II-6), formula (II-5), formula (II-4), formula (II-2) or formula (II-1) as intermediates, Among them, R 1a are independently selected from H, Cl and Br; R 2a 、R 4a 、R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R 3a are independently selected from methyl, ethyl, isopropyl, tert-butyl and benzyl; R 6a are independently selected from F, Cl and Br.

33. The compound according to claim 25 or its optical isomer, characterized in that The compound represented by formula (II-8) is prepared by the following method, comprising: subjecting the compound represented by formula (II-7a) to a borylation reaction.

34. The compound according to claim 26 or its optical isomer, characterized in that The compound represented by formula (II-7a) is prepared by the following method, comprising: subjecting the compound represented by formula (II-7) to a sulfonylation reaction.

35. The compound according to claim 26 or its optical isomer, characterized in that The compound represented by formula (II-7) is prepared by the following method, comprising: subjecting the compound represented by formula (II-6) to a ring-closure reaction.

36. The compound according to claim 27 or its optical isomer, characterized in that The compound represented by formula (II-6) is prepared by the following method, comprising: subjecting the compound represented by formula (II-5) to a ring-opening reaction.

37. The compound according to claim 28 or its optical isomer, characterized in that The compound represented by formula (II-5) is prepared by the following method, comprising: subjecting the compound represented by formula (II-4) to a halogenation reaction.

38. The compound according to claim 29 or its optical isomer, characterized in that The compound represented by formula (II-4) is prepared by the following method, comprising: subjecting the compound represented by formula (II-2) to a ring-closure reaction.

39. The compound according to claim 30 or its optical isomer, characterized in that The compound represented by formula (II-2) is prepared by the following method, comprising: subjecting the compound represented by formula (II-1) to a dehydration reaction.

40. Use of a compound of formula (II-8) according to claim 25 or 33 or an optical isomer thereof, or a compound of formula (II-7) according to claim 26 or 35 or an optical isomer thereof, or a compound of formula (II-7a) according to claim 26 or 34 or an optical isomer thereof, or a compound of formula (II-6) according to claim 27 or 36 or an optical isomer thereof, or a compound of formula (II-5) according to claim 28 or 37 or an optical isomer thereof, or a compound of formula (II-4) according to claim 29 or 38 or an optical isomer thereof, or a compound of formula (II-2) according to claim 30 or 39 or an optical isomer thereof, or a compound of formula (II-1) according to claim 31 or an optical isomer thereof in the preparation of a compound of formula (II-10).

41. A method for preparing a compound represented by formula (II-10) or an optical isomer thereof, characterized in that: The compound represented by formula (II-7a) is contacted with the compound represented by formula (I-11) to obtain the compound represented by formula (II-10) or an optical isomer thereof, in, R 5a Each is independently selected from H, tert-butyloxycarbonyl, 2-tetrahydropyranyl, benzyloxycarbonyl, acetyl, benzyl and p-methoxybenzyl; R 6a Select F, Cl and Br independently.